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Abstract 
 
 Cardiovascular disease is the number one cause of death in the United States, with 
myocardial infarctions adding to the severity of the disease. Infarcted tissue is dead heart 
tissue that no longer has contractile properties and is very brittle and thin. Professors at 
Worcester Polytechnic Institute are researching and refining a new technology known as 
Microthreads that have demonstrated the potential to aid in the regeneration of healthy 
heart tissue. The purpose of this study was to determine whether this technology is worth 
pursuing for the cardiac market. Based on the research conducted for this review, 
Microthread technology will have a promising future in the cardiac market when it is 
fully developed.   However, Microthread technology is still very early in its development 
and to limit its use to the cardiac field at this time is not considered the optimal direction 
to pursue in order to develop of its full market potential.   It may be more judicious at this 
stage of development for the architects of this technology to license the technology to 
other researchers, including the area of stem cell research, to increase the potential for 
this product to gain broad acceptance throughout the medical industry.  
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Executive Summary 
 
 Cardiovascular disease is the number one cause of death in the United States1. In 
2005, 80.7 million people were diagnosed or living with cardiovascular disease, 8.1 
million of whom had suffered from a myocardial infarction2. Of this 8.1 million, 156.8 
thousand people died as a result of the infarcted tissue of the heart. With so many people 
affected by this disease, and thousands more being diagnosed with this disease everyday, 
the medical establishment is on constant vigil for new and improved medical procedures 
and products that can help reduce or cure infarcted heart tissue.   
 Professor George Pins of Worcester Polytechnic Institute has patented a new 
biomedical product known as Microthreads, which can aid in the repair of infarcted heart 
tissue.  Microthreads are thread-like structures made of the naturally occurring proteins 
collagen or fibrin, which are biodegradable. The thread-like strands, as thin as a piece of 
human hair, can be seeded with therapeutic cells or other restorative agents along the 
exterior surface to create “living” threads.  These Microthreads can then be sewn directly 
into infarcted heart tissue, anchoring the seeded stem cells and/or therapeutic agents in 
the diseased tissue.  
 There are several medical devices and procedures currently available (listed 
below) that aim to duplicate this novel approach of delivering regenerative and 
therapeutic cells directly to the heart to treat infarcted tissue.  Unfortunately, they all fall 
short because they either do not have the capability of securing the quantity of therapeutic 
agents to the affected area or they are not capable of supporting the wide range of 
therapeutic agents that the structural matrix of the Microthread can. These techniques 
include: 
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• Injecting cells directly into the heart through the thoracic cavity 
• Balloon stents to deliver therapeutic cells embedded in the stent structure 
• Intravenously placing therapeutic cells into the blood stream and allowing them to 
travel to the heart 
• A heart patch that requires removing the dead portion of the heart, invasively 
through surgery,  and sewing new, healthy tissue into the gap  
 
 Professor Pins has requested this investigation to determine if a strong market 
potential for this technology exists and what steps should be taken to increase its 
likelihood of success in the clinical world. This investigation focused heavily on the 
cardiac market and the business potential for this product in that market. This research 
paper provides an overview on myocardial infarctions, the prevalence of this disease 
within the United States, cardiac care stakeholders, and competing technologies to 
establish a baseline to gauge the viability of this technology in the current medical 
market. The investigation also included a review of: product specific pricing, cost-benefit 
assessment, SWOT analyses, FDA regulations, insurance coverage and product licensing 
requirements.  
 Analysis has shown that, even with the limited scope of research completed to 
date, that Microthread technology has a promising future.  The inventors of this 
technology should act quickly to seize upon the opportunities identified in this paper to 
promote the use of Microthread technology in research and in the medical industry.  The 
inventors should develop a detailed action plan that includes: publishing informative 
articles in medical periodicals and research journals, a detailed development plan to 
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enhance the manufacture of Microthreads, map out the most appropriate route to clinical 
trials and investigate potential vendors to help in the development of a Microthread 
delivery system that is minimally invasive. 
 It is critical that the inventors secure legal aid to ensure they are in a position to 
grant licensing rights of this technology to medical professionals, researchers and 
commercial vendors as business opportunities present themselves.  This, more than 
anything, may provide the fastest avenue to success for this new and exciting technology. 
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I Introduction/Problem Statement 
 
A myocardial infarction, commonly known as a heart attack, is a result from the 
death of cardiac myocytes (heart muscle cells). This tissue death is due to a deprivation of 
blood, nutrients, and oxygen to the cells caused by a blocked coronary artery. This 
blockage can be caused by: an inflamed vascular wall placing additional stress upon the 
arteries, plaque build-up, or a blood clot restricting blood flow to the heart4. Deprived of 
vital resources the cardiac cells die, leading to drastic changes in the property of the 
tissue. As time wears on, the once healthy heart muscle is replaced by necrosed tissue 
which resembles scar-tissue. This tissue is much more rigid with limited contractile 
properties, is very thin and much weaker than the rest of the heart. The damaged tissue 
can lead to serious complications and death. It is assumed that if infarcted tissue is 
repaired it will regain the functionality of healthy heart muscle. 
 There are six different classification types of myocardial infarctions that a patient 
may suffer from, as shown in Table 1, provided by the American Heart Association3.  
The resulting tissue-death can be categorized in one of four ways3: 
§ microscopic focal necrosis 
§ small focal necrosis <10% of the left ventricular (LV) myocardium 
§ moderate focal necrosis 10-30% of the LV myocardium 
§ large focal necrosis >30% of the LV myocardium  
These classifications apply to all locations where a myocardial infarction may occur in 
the heart. Once the tissue is dead (and if the patient survives) then the damaged cells will 
begin to ‘heal’, leaving scar tissue as the remnants that replace the previously healthy 
tissue. 
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Table 1: AMA’s Clinical Classification of Myocardial Infarctions3 
 
 
Myocardial infarctions are a category within the larger group of cardiovascular 
diseases (CVD) which is the leading causes of death in the United States today. 
Researchers endeavor to create a device and/or method that will effectively treat or 
eliminate this detrimental disease. Currently, the concept of treating the cause of 
cardiovascular complications rather than the effects is dominating cardiac research.  
Treating the cause of a malady can reduce or eradicate all the effects produced by the 
illness.  
 Worcester Polytechnic Institute Professors Pins, Gaudette and Rolle patented a 
new biomedical scaffold known as Microthreads, a platform technology with direct 
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relevance to the cardiac market. A Microthread is approximately the size of one strand of 
human hair, and can be constructed out of collagen or fibrin (naturally occurring proteins 
within the body). These threads can then be seeded with therapeutic cells on the exterior 
surface. The cell-seeded threads can be bundled in groups of ten, threaded through or 
attached to a surgical needle and sutured into infarcted heart tissue. There are currently 
three different ways in which the Microthread technology can be sewn into the heart. The 
first involves sewing the cell-seeded threads along the outer perimeter of the infarction. 
The second is to sew two halves of an infarcted region together using the threads, 
creating a seam that promotes vascular regeneration. The third option is to create a weave 
of threads through the necrosed tissue, forming a living patch over the affected area. 
 Though this is an intriguing new technology with a multitude of positive 
attributes, there are still many factors that must be considered. This paper focuses on 
answering the question of whether or not Microthreads are worth pursuing. This was 
accomplished by analyzing their ability to stand up to the competition, receive regulatory 
and insurance approval, as well as having a chance to succeed against usual product 
challenges. Through the use of research, comparisons and analyzes the author of this 
paper gained a deeper understanding of the market and competition to determine the 
worth of Microthreads. This paper investigates the use of Microthread technology in 
healthcare from the stakeholders’ point of view.  The investigation included a review of 
competing therapies, government and industry regulations and overall cost.  This report 
addresses the hurdles Microthread technology must overcome and provides 
recommendations in order to become successful. 
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II Methods/Procedures 
 
 In order to determine the viability and practicality of Microthread technology in 
today’s medical industry, a comprehensive analysis of this new technology’s overall 
feasibility, cost and potential market position must be accomplished.  To gather the 
necessary background data and information on Microthreads and competing technologies 
a comprehensive review of available literature and interviews with industry experts was 
conducted.   
• Literature research 
o Scientific articles 
o Patents 
o Regulatory Agency documents  
o Various legal documents  
o A range of representative sample of insurance plans from industry leaders 
• Interviews 
o Professionals in their respective fields 
§ Cardiac 
§ Insurance  
§ Microthread technology 
The information gathered during this effort has been compiled and evaluated to provide 
valuable comparisons and analyses that may be used to establish where the Microthreads 
fall within today’s medical market. A SWOT analysis to evaluate the technology’s 
strengths, weaknesses, opportunities and threats within the cardiac market; and a Cost-
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Benefit analysis will give a straightforward look at the opportunities that exist with this 
technology.   
 The review of Microthread technology presented here is limited to and 
emphasizes cardiac care with open heart surgery as the baseline corrective medical 
procedure, unless otherwise stated. This was done to leverage current research work 
being conducted by researchers at WPI; their emphasis has been in the area of cardiac 
care. 
III Results 
 
 Based on the assumption that FDA approval for the use of Microthread 
Technology will be obtained and that a HCPCS code is acquired, this review has shown 
that a strong market potential exists for this technology in the cardiac care arena. 
This argument is based on the following: 
§ Current population who have suffered a myocardial infarction2: 8.1 million 
o People who will have their first infarction this year4: 600,000  
o People who will have a recurrent infarction4: 320,000  
§ Total inpatient hospital costs for CVD in 2005: $71.2 billion4 
§ Estimated Direct and Indirect cost of CVD for 2008: $448.5 billion4 
 
 While there are a substantial number of patients in this market, the exact number 
of people who would benefit from this technology is not known. This is due to the fact 
that there is no numerical data on the breakdown of people who suffer from acute, 
moderate and/or severe myocardial infarctions. The data is also subject to the quality of 
patient life, since it is variable by age, physical health and mental health. Despite these 
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unknowns, there are many who can benefit from this procedure. If this technology is used 
during open heart surgeries, then it could have been utilized in approximately 469,000 
operations in 2005. The market for this device will be even larger once it is perfected for 
minimally invasive procedures. This would not only allow it branch into the cardiology 
and stent market, this would allow for patients who otherwise rely on medications and 
rehabilitation to treat their symptoms to increase their quality of life.  
 This product differs greatly from products on the market currently and in known 
development. Unlike many of its competitors, Microthreads have the potential to be used 
in two of the main heart care arenas: open heart surgeries and minimally invasive 
procedures. In addition to this, Microthreads technology has the ability to effectively 
place cells within infarcted tissue and allow the cells to regenerate.  
 Definitive pricing is not known for many of the developmental technologies due 
to their proprietary nature and a need-to-know basis. It is safe to assume that 
Microthreads are likely to be less costly than their major competitors based on their 
anticipated ease of use and manufacturing process. The developmental cost of 
Microthreads is far less than the development of most technologies and utilizes materials 
from readily available resources. This technology can be integrated into pre-existing 
procedures, such as open heart surgery or cardio-endoscopy, allowing for the threads to 
be more cost-effective in the long run. 
 Microthreads have the potential of virtually unlimited application within living 
organisms. The cardiac applications examined here are merely the foundation that will 
define Microthreads’ capabilities and uses since they are, in essence, a platform 
technology. While the myocardial applications appear to be a highly beneficial area to 
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investigate, once the market has been established, this product can be used to treat other 
diseases as well. Microthread technology could be applied to improve patients who suffer 
from: multiple sclerosis, ligament damage, severed spinal chord, stroke, chronic wounds 
and liver or kidney damage. This will allow for a continuous growth in the life cycle of 
the Microthread market.  
 The benefits of Microthread technology outlined in this paper are evidence of this 
products likelihood to succeed in the medical market today and in the future. By treating 
the cause of the problem rather than the effects, Microthreads can improve the quality 
and length of life for many people who suffer from myocardial infarctions. Not only does 
it treat the immediate problem, it helps eliminate additional heart damage that can be 
caused by strain placed on the healthy tissue. This will likely mean fewer subsequent 
hospitalizations, lower cost to insurance companies and patients, and an enhanced life for 
those who have suffered infarctions. With the low projected costs, the strong market 
need, and the benefits of this medical treatment, Microthread technology is a worthwhile 
pursuit. The key to the success of the threads remains with the continued improvement of 
the technology while pursuing the market requirements simultaneously. 
 In order to advance the use of this new medical treatment, it is this author’s 
opinion that greater focus needs to be applied within both the marketing and 
engineering/research arenas. The architects of this technology must generate a business 
plan for the future marketing of their device. They must use their knowledge of where the 
product development is currently to create milestones and to begin the informative 
process of the FDA regulatory board in addition to filing for a HCPCS code for their 
device if their choice is to actively market this product.  At a minimum, licensing 
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agreements must be investigated and pursued to ensure the intellectual property for this 
technology is protected. Once licensing has been arranged, the technology will be 
available to other researchers in various medical fields where seeding of regenerative or 
stem cells require the unique properties of Microthreads for implantation.  If this is not 
accomplished in a timely manner then the market release and clinical trials of this product 
could be exposed to unacceptable delays.  
IV Discussion 
IV.1 MEDICAL & MICROTRHEAD TECHNOLOGY OVERVIEW 
IV.1.1 Medical Review of Myocardial Infarctions 
 
As discussed earlier, one of the main causes of cardiovascular problems is 
infarcted heart tissue. The term infarcted corresponds to tissue death due to a lack of 
blood, oxygen and nutrients. Deprived of vital resources the cells die, leading to changes 
in the property of the tissue. As time passes after a heart attack, healthy heart muscle is 
replaced by necrosed tissue which resembles scar-tissue. This tissue is much more rigid 
with limited contractile properties; it is very thin and much weaker than the rest of the 
heart5. The damaged tissue can lead to serious complications and death if untreated. 
Anecdotal evidence points to the assumption that if infarcted tissue is repaired it will 
regain the functionality of healthy heart muscle.  
IV.1.1.1 Number of CVD/Myocardial Infarction cases in the US 
 
 The numbers of people who suffer from cardiovascular disease and/or myocardial 
infarctions (MI) indicate how large the target market is for Microthreads.  In 2005, 80.7 
million people had been recently diagnosed with or were already living with some form 
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of cardiovascular disease. 8.1 million of these people suffered from a Myocardial 
Infarction2.  It is projected that in 2008 that an additional 600,000 people will suffer from 
a new heart attack, while 320,000 will experience a subsequent attack2. With so many 
people affected by this disease, and thousands more being diagnosed with this disease 
everyday, the market potential for this product continues to grow.  
IV.1.1.2 Death Rate 
 
 Cardiovascular disease (CVD) is the number one cause of death in patients with 
chronic disease in the United States1. In 2005, CVD accounted for 35.2% of all deaths in 
the United States. This percentage has remained fairly constant over the years. 
Approximately 2400 Americans die from CVD every day (876 thousand people every 
year), and 32% of these deaths occur in people younger than 75.  Of these CVD related 
deaths, 156.8 thousand people died annually from myocardial infarctions 4.  This is a 
small fraction of the total number of people who have suffered from a myocardial 
infarction, making up only 2% of the total patients who experienced a heart attack. 
IV.1.1.3 Survival Rate 
 
Currently, there are roughly 7.9 million Americans who have survived a 
myocardial infarction. Many of these people return to relatively normal lives and work 
within two weeks to three months after the attack depending on the severity of the 
infarction.  Typically patients make some concessions in their daily routines as they adapt 
to physical changes brought about by a heart attack and are usually advised to undergo a 
rehabilitation regiment to learn how much strain is safe to put on their heart. 
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Rehabilitation normally begins as soon practicable after the heart attack and continues 
through the heart’s healing process. .  
IV.1.1.4 Quality of Life 
 
 The changes in the quality of patients’ lives after a myocardial infarction can 
range from relatively minor to severe based on both the physical damage done to the 
heart and the psychological trauma caused by the attack on the patient.  Physical ability 
can be limited due to the extent of the infarcted tissue.  If the injury is small then it often 
is not noticeable to patients.  Larger areas of infarcted tissue greatly reduce the heart’s 
functional level and limit the amount of physical work a patient can perform.  This 
limitation is the result of additional strain placed on the non-infarcted tissue 
compensating for the decrease in overall heart muscle.   In some cases this stress is too 
great for patients to return to their previous lifestyle.  Increased stress on the heart also 
tends to increase fatigue in many patients, as the heart works harder to keep up with day-
to-day activities.  Medications such as digoxin increase the strength of the non-infarcted 
tissue and allow these patients to better perform physical activities though they may be 
limited in what tasks they can perform.  
 After a heart attack, patients are prone to feel a wide range of emotions for two to 
six months after the incident6.  The most common emotions for patients to experience are 
depression, fear and anger7.  It is considered normal to experience these emotions directly 
after the event, but these feelings should subside. If the depression, fear and anger 
continue it can severely affect the quality of patients’ lives. The fear and general 
apprehension of having another heart attack can cause a patient to avoid both the normal 
activities and rehabilitation that would otherwise improve their chances of avoiding 
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further attacks.  Depression is considered one of the most dangerous side effects due to 
the multitude of areas it affects and the fact that it can remain hidden.  This emotion can 
interfere with sleeping, eating, self-esteem (feeling worthless) and can create thoughts of 
suicide.  It is very important for patients who experience these emotions to talk to their 
families and their healthcare professionals. The only way their quality of life will 
improve is if they take active steps to address these emotional problems. 
IV.1.1.5 Cardiac Rehabilitation 
 
 Following any major cardiac episode patients are encouraged to enter into cardiac 
rehabilitation.  This is a medically supervised program which includes a regimen of heart 
medications as well as physical therapy to improve the overall health of the patient and 
diminish physical limitations. A study conducted by the Division of Cardiology, 
Ospedale Maggiore di S. Giovanni Battista, di Torino, Italy, showed that “[rehabilitation 
participants] had a significantly higher work capacity, a higher double product reached 
during the stress test and lower triglycerides… patients were more symptom-free (44% 
against 30%)… 6.1% of the R[ehabilitation] group and 11.2% of the C[ontrol] group 
developed a new myocardial infarction8.” This indicates that there is a 45.5% decrease in 
the recurrent heart attacks in the rehabilitation group compared to the control, a 
significant difference in overall health. 
 Despite such positive results, rehabilitation programs tend to go unused by a 
significant portion of heart patients. Women are 55% less likely than men to participate 
in these programs, and older patients are less likely to participate than their younger 
counterparts.  Patients over the age of 70 have a participation rate of 32%, a relatively 
low percentage given the predominance of the disease in this age group.  In the 60-69 
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year old group, 66% of patients are actively involved in rehabilitation; and 81% of 
patients younger than 60 participate in the rehabilitation programs9. While the 
involvement in all age groups is far less than it should be, of all the age groups only 17% 
complete the entire rehabilitation program4.  
Factors that affect participation: 
§ Costs: Rehabilitation starts the moment a patient enters the hospital with a 
cardiac episode and continues for three to six months afterwards.  Rehabilitation 
involves a large number of medical professions and time consuming medical 
appointments and therapy sessions.  The bills can become very steep and older 
patients are not always able to afford treatment.  This is particularly true if 
insurance does not cover all aspects of the rehabilitation effort.  Medicare covers 
most of the costs, but requires patients to pay $135/yr for the coverage, in 
addition to paying 20% of Medicare approved amounts10.  To older patients with 
a limited income, this can make pursuing cardiac rehabilitation unrealistic. 
Learning how to function after a heart attack without experienced medical help 
can be far more appealing than the stress from ever mounting medical bills.  Any 
procedure that could cut these costs would likely be very appealing to the elderly.   
§ Patient psychology:  Patients fall into extremes when it comes to reasons for not 
participating in the program. Studies have found that patients fall into a wide 
range of categories:   
o Ruled by fear - This group typically believes rehabilitation may trigger a 
further myocardial infarction or incident. 
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o All Knowing - These patients believe they do not need the therapy 
because they ‘know” exactly what their limitations are.   They do not 
need to waste the time and money as they already know how to handle 
their situation.  
o Post-MI depression - This is very common creating a “what does it 
matter” mentality towards every aspect of their recovery.  If it is not 
diagnosed, they may fall out of treatment completely.  
§ Patient gender:  The highest incidence of myocardial infarctions occurs within 
the ranks of the elderly.  Of this group, men tend to pursue rehabilitation more 
frequently than women.  Conventional wisdom suggests that elderly men pursue 
rehabilitation more frequently because their spouses are alive to provide support. 
Women, on the other hand, live longer then their male counterparts and are more 
likely to be on their own when illness strikes.  This lack of spousal support may 
explain the decreased frequency of women undergoing cardiac rehabilitation.  
IV.1.1.6 Infarcted Tissue vs. Healthy Tissue 
 
 The heart has three distinctive layers of cardiac muscle fibers: the endocardium (a 
thin inner layer of epithelial tissue), the myocardium (a middle layer cardiac muscle) and 
the epicardium (a thin external layer of epithelial tissue)11. For the purposes of this 
analysis, the application of Microthread technology focuses on the myocardium.  The 
cardiac muscle fibers within the myocardium are arranged in a spiral pattern around the 
circumference of the heart. The ventricular muscle contracts and shortens the diameter of 
the ventricular chambers as the apex is simultaneously pulled upward, directing the blood 
toward the openings of the heart’s major arteries11.  This wringing effect creates the heart 
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beat. The beat of a healthy heart is regulated by a series of electrical impulses that causes 
the cardiac muscle fibers to contract and the heart to pump efficiently.  These electrical 
impulses are regulated by two nodes, the sinoatrial node (SA node) and the 
atrioventricular node (AV node). The cue to start the contraction is sent from the SA node 
down to the AV node, the signal is then sent down a tract of specialized cells, known as 
the Bundle of His, located in the interventricular septum (the tissue that separates the 
right and left ventricles). The Bundle of His branches off into small fibers (known as 
Purkinje fibers) that extend throughout the ventricular myocardium, allowing the signal 
to travel throughout the muscle fibers, causing the ventricular contractions to begin.  
    
 
Figure 1: Healthy Heart vs. Infarcted Heart 
Left: Healthy Heart Muscle12 
Right: Infarcted Heart Muscle, off-white strip on the upper section of heart muscle is infarcted tissue.13 
 
When the muscle is deprived of oxygen and blood, it will die forming an area of necrosed 
tissue on the heart. This necrosed muscle will slowly be replaced by scar tissue, 
composed primarily of fibroblasts and type III collagen14.Collagen type III is a fibrillar 
collagen that is found in many tissues, especially within blood vessels, and it plays a 
major role with tissues that exhibit elastic characteristics15. While this type of collagen is 
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present in many elastic tissues, collagen type III has minimally elastic properties. “The 
infarcted regional elasticity [of the scar tissue] depends on the ratio of fibrous to muscular 
tissue and the density of the collagen cross-links [that develops as the infarction heals]”14. 
This makes the area of the infarction very weak and the stress of pumping blood further 
fatigues the scar tissue over time, so that the infarcted area may grow further decreasing 
heart function.  Infarcted tissue is not only much more brittle than the muscle that it 
replaces, it is also much thinner. A visual example of this damage can be seen in Fig.1. 
The infarcted region of the heart can continue to thin over the course of a patient’s life as 
the mechanical stresses of the heart bear on the scar tissue. 
IV.1.1.7 Open Heart Surgery 
 
 To be considered as a candidate for this surgery, a person must suffer from one or 
more of the following conditions: congenital heart disease, damaged or diseased heart 
valves, severe heart disease that requires a heart transplant or severe blockage of the 
arteries that necessitates bypass surgery. In addition to this, the patient must be healthy 
enough to withstand the stress of a major surgery. These patients must be willing to take 
the risk of complications that result from open heart surgery as well as the grueling 
rehabilitation process that follows16.  
 Open heart surgery is an extremely invasive procedure with serious implications. 
Complications can range from mild to life threatening.  The most basic complications are 
post operative bleeding, infection, numbness, and nausea.  Serious complications include 
stroke, heart attack, graft failure, pneumonia, lung or kidney failure, nerve or organ 
damage and death. In 2006, there were a total of 694,000 open heart surgeries in the US, 
448,000 of those were bypass surgeries which closely relates to myocardial infarctions17. 
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IV.1.2 Review of Microthread Technology 
IV.1.2.1 Microthreads 
 
 The premise behind Microthread Technology is to provide a support structure, a 
scaffold, which will permit therapeutic cells to be anchored to damaged tissue with the 
intent of promoting cell growth and regeneration of healthy tissue within the body.  
Patented in 2007-2008, Microthreads is a new biological technology that has been 
developed by Professors Pins, Gaudette and Rolle from Worcester Polytechnic Institute. 
A Microthread is a long biopolymer strand constructed out of either fibrin or collagen and 
is approximately the diameter of one strand of hair. 
 
Figure 2: Unseeded Microthreads, Close Up18 
 
Figure 3: Seeded Microthreads, Close Up18 
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 The biopolymer threads are seeded with human mesenchymal stem cells (hMSCs) 
cells along the exterior surface (Figs.2-3), or in a co-culture system that is currently being 
tested.  For myocardial applications, the threads are bundled into groups of ten and 
looped through the eyelet of a needle or attached to a cellular sheath.  The Microthread 
bundles are then sutured in and around the infarcted area of the heart (Fig.4). In addition 
to being used as simple sutures around small areas of infarcted tissue, it is envisioned 
that, in the future, Microthreads can be woven over a larger infarction area 19,20,21.  
 
Figure 4: Microthread Diagram18 
 
 Ultimately the bundle will be covered by an outer sheath that will reduce or 
prevent shearing of base cells and tissue as the Microthread bundle is passed through the 
myocardium.  The outer biodegradable sheath and Microthread bundle are left in the 
heart to regenerate tissue (seen below in figure 5), while the needle and excess threads are 
cut off and removed.  
 
Figure 5: Microthread Suture Diagram18 
1 
2 3 4 
1 – The Myocardium 
2 – Microthreads with Sheath 
3 – Surgical Needle 
4 – Excess thread and needle removed 
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Figure 6: Microscopic Cross-Section, Rat Myocardium and Microthread Bundle18 
 
 Animal testing of Microthread technology to evaluate the basic mechanical 
properties of the threads and gauge their overall effectiveness is ongoing.  Professor 
Gaudette sutured a bundle of Microthreads into a living rat’s heart as part of the 
investigation.  This was accomplished using the same or similar procedures and protocols 
that are used for human open heart surgery.  Figure 7 shows the bundle of Microthreads 
as it passes through the heart wall attached to the surgical needle. 
 
Figure 7: Suturing Microthreads into Rat Heart18 
 
 Professor Gaudette found that the threads were easy to use and did not break 
under the stresses of suturing.  In addition, the threads remained anchored in the heart and 
Microthreads 
Needle 
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appeared to stimulate angiogenesis (formation of new blood vessels).  The exact amount 
of tissue the threads can repair is still unknown, but will be explored as animal testing 
continues in larger animals.  The sutured threads can be seen on the outer surface of the 
Rats heart along with the beginning of angiogenesis in Fig.8.  
 
Figure 8: Rat Heart Sutured with Microthreads18 
White arrows are pointing to the Microthread sutures 
 
IV.1.2.2 Microthread Technology 
 
 Microthread technology offers numerous potential benefits to greatly improve 
patients’ lives.  The simple geometry and flexibility of Microthread fiber will provide 
cardiologists and surgeons a great deal of latitude in their use and application.  
Microthreads have few limitations beyond the mechanical strength of the basic 
biopolymer fiber.  The composition of the threads is a key attribute that differentiates it 
from anything on the market today. By using collagen and fibrin threads, scaffolding 
which in the past has been overlooked due to structural properties, the creators have 
formed biodegradable threads from naturally occurring proteins. This property lowers the 
chance of a negative immunoresponse from the patients. 
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As stated earlier in this paper, Microthreads are in essence living threads, seeded 
with therapeutic cells along the exterior surface, which can be anchored to damaged 
tissue to promote cell growth and stimulate angiogenesis.  These threads can be sutured 
into the heart utilizing a range of medical methodologies.  Suturing single threads and 
thread bundles along the edge of the infarct can promote cell growth along the perimeter 
the repaired area. Weaving a mesh of Microthreads, through and over the infarcted heart 
tissue, can create a living patch within the heart wall that can stimulate cell growth from 
the inside and out.  In instances where medical procedures require wholesale removal of 
heart tissue as seen with a Batista Procedure, Microthread technology could be utilized to 
join the bisected heart together while promoting the growth of cells between the two 
halves.   
Minimally invasive procedures encompass the future cardiac applications of this 
technology. Cardiac endoscopy and similar medical procedures could be used to deliver 
the Microthreads to the affected areas of the heart.  Currently, endoscopes with diameters 
of 5mm and 3mm are utilized for sewing heart valves and coronary arteries via small 
incisions in the thoracic cavities22. These procedures would allow the Microthreads to be 
sutured into failing heart tissue with minimal stress on the patient.  Minimally invasive 
procedures similar to endoscopy also have the advantage of lowering patients’ pre-
qualifications requirements for surgery because they are much less taxing on the body.  
Medical procedures to place Microthreads in the heart would likely be conducted on an 
outpatient basis, requiring approximately one full day to complete with no overnight 
observation required except in special cases.   
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 Enhanced placement of therapeutic agents during major heart surgeries and 
anticipated use of minimally invasive procedures to treat less complicated heart problems 
can increase the range of patients that can benefit from new cardiac therapies using 
Microthreads. 
IV.1.2.3 Microthread Fabrication 
 
 Fibrin Microthreads are created through a co-extrusion process which involves 
solutions of fibrinogen and thrombin. The fibrinogen is dissolved in a HEPES buffered 
solution and the thrombin is a stock solution in HBS. The fibrinogen and thrombin 
solutions are then warmed to 37°C and placed into separate 1mL syringes. These 
solutions are coextruded through a blending applicator tip which connects both syringes. 
As the solutions are combined, they are extruded through a polyethylene tubing (0.38mm 
in diameter) into a bath of HEPES at room temperature. The threads are then hand-drawn 
through the bath. The threads are removed from the bath and air dried under the tension 
of their own weight. The Microthreads are then stored at room temperature in a 
desiccator until they are used. When the threads are needed, they are rehydrated in PBS, 
sterilized in 70% isopropyl alcohol and then rinsed in sterile PBS. The sterilized threads 
are then seeded with cells (typically hMSCs) in media and incubated19. 
 
 32
 
Figure 9: Fibrin Microthread Extrusion Equipment19 
 
 Collagen Microthreads are created through a similar process. Rather than co-
extrusion, collagen Microthreads are singularly extruded through a 0.38mm diameter 
polyethylene using a syringe pump. The collagen threads are then extruded into a bath of 
fiber formation buffer, then moved into fiber incubation buffer and finally into distilled 
water. The threads are then air-dried under the tension of their own weight and seeded 
with cells (hMSCs) as the fibrin threads were19. 
IV.1.2.4 Future Microthread Manufacturing Methodology 
 
 Microthreads are currently manufactured in less than a day, by hand and in small 
batches, using a portable extrusion device created by Professor Pins of WPI.  
Microthreads are manufactured on location; the threads are not prefabricated at this point 
due to concerns with maintaining the threads in a sterile environment.   It is also unclear 
as to how much time the adding a patient’s own adult mesenchymal stem cells to the 
Microthreads would affect the production time of the threads. This uncertainty is due to 
the early stages of the production of the threads and will improve as more research is 
conducted as the project moves forward. At this time the team has not considered onsite 
fabrication and seeding of the threads20,21.  
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 When clinical trials occur, the Microthreads will have to be manufactured on 
location. Eventually the manufacturing process will progress to a contained, sterilized 
environment that will still require the human touch to take the threads out of the buffer 
solution. The creators of Microthreads hope to one day utilize a bioreactor to hold 
Microthreads and seed them with a specific patient’s cells.  
IV.1.2.5 Packaging 
 
 In the long run, Professor Pins hopes to create a bioreactor that would be capable 
of sustaining large quantities of Microthreads that could be seeded with the correct type 
of cell and then shipped to the respective locations20,21,23. 
IV.1.2.6 Shelf-life of Microthreads 
 
 While this has yet to be tested or characterized at this point, the team has stored 
threads for at least two weeks in their laboratory and used them later with success. At this 
point the timeframe for the optimal effectiveness of the microthread in its life has yet to 
be established or researched20,21,23.   
IV.1.3 Follow-on Microthread Research 
 
 Biopolymer Microthread technology is in its infancy.  As such there are still many 
medical and technical issues that must be managed and addressed before the product will 
be ready for the medical market.  The areas of concern that will be addressed through 
research and further animal testing include: 
• Investigate the limitations of Microthread therapies –   
• Effectiveness of  Microthread(s) to provide various therapeutic strategies 
to infarct damage. 
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• Effectiveness of seeded Microthread(s) to regenerate cells and tissue in 
infarcted areas of the heart. 
• Evaluate complications from the use of Microthreads including the 
potential for developing scar tissue.  
• Investigate the biological mechanisms that inhibit repopulation of cells in a 
seeded area and identify inhibiting factors. 
• Develop a biodegradable sheath to house Microthread bundles that will prevent 
sheering of the tissue and basal cells. 
• Develop or modify existing minimally invasive medical procedures to introduce 
Microthread based therapies to affected areas of the heart. 
• Investigate to determine the immunoresponse of humans to the bovine collagen. 
• Investigate methods to produce and manufactured Microthreads on a large scale 
in a sterilized environment. 
IV.1.4 Other Microthread Marketing Opportunities 
 
 While the cardiac market is very large and can benefit greatly from Microthreads, 
there are many other disease segments within the health market that can potentially be 
treated with these threads. This is due to the fact that Microthreads are a platform 
technology, since the scaffolding can remain the same and the cells that are seeded along 
the exterior can be changed to support regeneration of various tissues or cells and 
therapeutics agents.  
 Once the technology has been fully developed and the cardiac market successful 
infiltrated, it is this author’s opinion that this product can then be extended to many 
opportunities including: 
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§ Multiple Sclerosis (MS) – A chronic disease of the nervous system that slowly 
breaks down the nerves and nerve tissues of the patient.  This is an unpredictable 
disease that results in very difficult and painful symptoms that include: blindness, 
numbness, tremors and fatigue. In the nervous system the nerve cells are protected 
by a myelin sheath made up of oligodendrocytes.  MS attacks the myelin sheaths, 
which surround the nerve cells, leaving the nerve completely exposed.  It may be 
possible for surgeons to use Microthreads to deliver pre-oligodendrocyte cells to 
nerve rich areas and promote growth of myelin sheaths, reversing the damage that 
causes MS.  
§ Ligament Damage – Any ligament that is torn throughout the body could be 
repaired using Microthreads. A typical ligament is 90% collagen I, 9% collagen 
III and 1% fibroblasts. By varying the method of bundling and seeding of 
Microthreads, biomedical engineers and physicians could manufacture 
replacement ligaments for patients, eliminating the need to transplant ligaments 
from other parts of the body. 
§ Spinal Chord Injury – A spinal chord injury is devastating.  The surrounding 
tissue and resultant neuron death has been an insurmountable problem for doctors 
and surgeons.  In the future it may be possible to adapt Microthreads technology 
to repair the tissue surrounding the chord as well as delivering regenerative cells 
to improve or regenerate neurons and their functions.  Direct delivery of 
therapeutic agents and regenerative cells could help reduce paralysis and pain.  
§ Stroke – The most common type of stroke is ischemic and occurs when arteries 
are blocked by blood clots, fatty deposits or plaque build-up.  Approximately two 
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million brain cells die every minute when an area of the brain is deprived of 
critical blood flow.  This poses a high risk of permanent brain damage, disability 
and/or death.  The necrosed brain tissue resulting from a stroke may be treated 
similarly to infarcted heart tissue in the future.  While the functions and abilities 
that were controlled by the area of the brain affected during the stroke are lost 
permanently, a procedure with Microthreads could deliver regenerative cells 
through minimally invasive routes or during brain surgery.     
§ Chronic Skin Wounds – Chronic wounds are typically very painful that do not 
heal. There are three major categories of chronic wounds include: venous ulcers, 
diabetic ulcers and pressure ulcers (bed sores).  Microthreads may be introduced 
by the surgeon to help the patient’s body heal with regenerative cells and the 
additional support of angiogenesis.  Utilizing a woven Microthread structure it 
may be possible to cover and close the wound, effectively creating a living patch 
of healthy tissue. The thread structure would likely be seeded with  therapeutic 
agents that reduce infections and promotes healing. 
§ Liver/Kidney/Organ Damage – Like the cardiac therapies described earlier in this 
paper, Microthread technology may be utilized to regenerate necrosed or injured 
tissue in the liver, kidney and other organs.  Again, utilizing minimally invasive 
procedures, Microthreads could help repair tissue to reverse the effects of disease 
such as cirrhosis of the liver or may be used to reverse the effects of physical 
trauma (a result of a car accident or other physical violence) on the organ as well.   
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IV.2 COST DRIVERS AND ANALYSIS 
IV.2.1 Stakeholders in the Cardiac Industry 
IV.2.1.1 Cardiologists 
 
 Cardiologists are physicians who identify and treat diseases of the heart and blood 
vessels.  Typically the cardiologist is the first medical professional a patient will see for 
heart related conditions and concerns.   The cardiologist is highly trained to diagnose 
heart related illness through review of medical history, examinations and routine tests.    
Cardiologists regularly perform minimally invasive procedures that include cardiac 
catheterizations (inserting balloon catheters into the coronary arteries) as part their patient 
evaluation.  This ability to proficiently perform minimally invasive procedures, that 
include cardiac catheterizations, may be leveraged to perform similar procedures utilizing 
Microthread technology.    
Market Benefit to the Cardiologist –  Increased client base. 
Cardiologists will be able to perform Microthread implantation eliminating the need 
to send patients/clients to cardiac surgeons.  This will enhance the cardiologists’  
patient/market share. 
IV.2.1.2 Cardiac Surgeons 
 
Cardiac surgeons perform intense, invasive procedures on the heart and/or great 
vessels.  Surgery is performed to treat complications of ischemic heart disease (for 
example, coronary artery bypass grafting), correct congenital heart disease, or treat 
valvular heart disease created by various causes including endocarditis.  Microthreads 
therapy offers the surgeon a new tool to effectively seed regenerative cells, graft heart 
patches and apply medical therapies to the myocardium during open heart surgery.  If 
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testing confirms that microthreads have sufficient strength, it may be possible for the 
surgeons to replace the sutures currently used during surgery with seeded Microthreads. 
This offers the possibility of faster and more complete healing of the patient’s heart tissue 
following surgery.  
Market benefit to the Cardiac Surgeon – Increased client base. 
Microthread technology will likely to decrease the “low risk” patient/client base. This 
includes the procedures performed by Cardiologists.   
Due to the less invasive nature of this technology, cardiac surgeons will be able to 
perform procedures on high-risk patients that currently don’t qualify for surgery.  The 
technology has the potential to improve the overall quality of the surgery/service provide 
by the surgeon.  Since the Microthread technology may increase the life span of the 
patients, the surgeons would benefit monetarily from longer or more fulfilled long-term 
surgery follow-up appointments.  
IV.2.1.3 Patients 
 
 Patients, as the end users of these Microthread therapies, have the most to gain 
with this new technology. Through the use of minimally invasive Microthread 
technology, patients will have the potential for decreased downtime from surgery, faster 
healing and increased heart strength and functionality. 
Market benefit to the Patient – cost and time savings. 
It is anticipated that the overall quality of the patient’s/client’s life will increase with 
a decrease in overall cost and effort.  
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IV.2.1.4 Biomedical Engineers 
 
Biomedical engineers invent, expand and market new medical technologies like 
Microthreads.  With the successful approval and use Microthread technology by the 
medical sector, further use and expansion of this field is anticipated.  Currently 
biomedical engineers envision that the use of Microtheads, as cellular scaffolds, hold 
limitless possibilities for rehabilitation in the human body.  Threads woven together to 
form patches, could be seeded with base cells, in essence creating living patches. These 
“living” patches could then be layered with other “living” patches until an entire area of 
organ tissue could be grown. This could ultimately lead to the regeneration of organs by 
creating scaffold of living tissue.  
Market benefit to the Engineer – high growth potential.  
This is a new industry with promising potential. 
IV.2.2 Cost Review and Analysis 
IV.2.2.1 Cost of Microthreads 
 
 In order to be successful in a competitive market, it appears that Microthreads 
must be manufactured and utilized for under $363.  This value is based on the results 
provided in Table 2, which explores the cost of medicinal treatments over the course of a 
patient’s remaining life. Table 2 was derived from the medicinal cost matrix (Appendix 
3) and has the three top drug combinations that the author found to be most commonly 
used by cardiac rehabilitation patients: Digoxin, ACEI and Beta Blockers. 
 The dosage along with the brand of the drug combinations aims to show the 
minimum, mean and maximum pricing for each medication. For example, in the Digoxin 
and ACEI section Lisinopril 10mg represents the minimum cost for an ACEI, while 
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Captopril 100mg represents the expensive ACEI types and Ramipril 10mg is the average 
price of multiple ACEI’s. The author did this to give a clear understanding of the 
medicinal combinations in general, since a matrix with all drugs and dosages would be 
quite difficult to understand.  
Table 2: Medicinal Cost Matrix - Life Expectancy 
Medication 
Combinations Cost per year
Digoxin 7.4† 10.4‡ 6.4* 2.0#
Digoxin 0.125mg $182 $1,344 $1,888 $1,162 $363
Digoxin 0.25mg $248 $1,838 $2,583 $1,590 $497
Digoxin + ACEI
Digoxin 0.125mg 
+  
Lisinopril 10 mg
$398 $2,942 $4,135 $2,544 $795
Digoxin 0.125mg 
+  
Captopril 100 mg
$3,434 $25,408 $35,709 $21,975 $6,867
Digoxin 0.125mg 
+  
Ramipril 10 mg
$962 $7,116 $10,000 $6,154 $1,923
Digoxin 0.25mg 
+  
Lisinopril 10 mg
$464 $3,437 $4,830 $2,972 $929
Digoxin 0.25mg 
+  
Captopril 100 mg
$3,500 $25,903 $36,404 $22,403 $7,001
Digoxin 0.25mg 
+  
Ramipril 10 mg
$1,028 $7,610 $10,695 $6,582 $2,057
Median Survival Years
 
 
 
 
 
 
 
 
 
 41
 
Table 3: Medicinal Cost Matrix - Life Expectancy ~ Continued 
Medication 
Combinations Cost per year
Digoxin + BETA
Digoxin 0.125mg 
+  
Metoprolol tartrate 50 mg
$290 $2,143 $3,011 $1,853 $579
Digoxin 0.125mg 
+  
Carvedilol 12.5 mg
$1,670 $12,355 $17,363 $10,685 $3,339
Digoxin 0.125mg 
+  
Atenolol 50 mg
$746 $5,517 $7,754 $4,772 $1,491
Digoxin 0.25mg 
+  
Metoprolol tartrate 50 mg
$356 $2,637 $3,707 $2,281 $713
Digoxin 0.25mg 
+  
Carvedilol 12.5 mg
$1,736 $12,849 $18,059 $11,113 $3,473
Digoxin 0.25mg 
+  
Atenolol 50 mg
$812 $6,012 $8,449 $5,199 $1,625
† Median patient survival years for women 60-69yrs, men 70-79yrs
‡ Median patient survival years for women 70-79yrs
* Median patient survival years for women ≥ 80yrs
# Median patientsurvival years for men ≥ 80yrs
Median Survival Years
 
 The costs to use these medicines per year in this table were determined based on 
the average dose per day and the number of capsules usually prescribed to obtain a yearly 
cost24. The price of medication for each individual month was calculated and the total 
costs for all twelve months were combined to obtain the yearly cost. The yearly cost was 
then multiplied by the median survival year brackets located across the top of the table. 
Hospital, physician and other medical costs are not included in this analysis since those 
costs would be consistently applied across current medical procedures. Patients would 
incur these medical costs due to their illness regardless of the medications prescribed.  
The survival years represent the median life expectancy of a patient who survived a heart 
attack over the age of 60 (figures provided by the AHA4). The median years are not listed 
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in a numerically ascending or descending order; rather it follows the age groups of 
patients who have survived a heart attack (shown in key at bottom of the table). To 
determine the total medicinal costs to a patient, the cost of the medicinal treatment per 
year was multiplied by the median survival year to arrive at the cost (located in the body 
of the table).  
A review of the table shows that the minimum cost of supplying the heart 
medication to a patient falls under the use of digoxin (a form of digitalis) for a person 
surviving two years after their myocardial infarction.  Based on this, Microthreads must 
be manufactured and utilized less than or equal to $363. 
IV.2.2.2  Cost-Benefit Analysis 
 
To date, $23,400 (in the form of a grant) has been spent on the development of 
Microthread technology.  WPI Professors anticipate that a second grant for $405,000 will 
be received to allow for scale up and validation of the Microthreads in an animal model21, 
bringing the total to $427,400.  Conservatively, an additional ~$500,000 will be required 
to complete preliminary research and prepare for clinical studies.  Based on this, the 
preliminary development cost of this devise to estimated to be $1million.  This cost of 
development is low enough to have a negligible effect on the per piece price of 
Microthreads.   
If the purveyors of this product choose to bring the technology through clinical 
trials, then the developmental costs will increase dramatically. According to Thomson 
Center Watch, the cost of clinical trials is approximately $25,000 for each patient 
involved in the study25. If the trials are conducted on 2,000 patients, clinical trials alone 
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would cost $50million. The increased cost in clinical trials is great enough to have an 
effect on the price per piece of the Microthreads.  
Assuming the procedure used to implant the Microthreads will be minimally 
invasive in nature, similar to endoscopy or cardiac catheterization, the average cost for 
the procedure would be approximately $2500.  This is based on the following cost data 
derived from readily available medical literature: 
§ The maximum price of manufacturing, use and development costs cannot exceed 
$363 per thread when averaged over the life of the product 
§ The price of $624 for hospital and physicians’ services is per day26 
§ The average price of a GI endoscopy is $1,398 27 
This cost is much lower than current, more invasive, medical procedures that 
include open heart surgery.  Indicating at a high level that the anticipated cost does not 
out weigh the benefit of this device; showing Microthreads may be a beneficial venture to 
pursue. 
 Additional benefits that do not necessarily have direct cost related to them but 
show a strong potential to benefit the patient include:  
§ Repairing otherwise useless tissue 
§ Bringing the heart back to full-working capacity 
§ Improving the quality of patients’ lives 
§ Enhancing patient longevity 
§ Eliminating subsequent hospitalization for recurrent issues caused by infarcted 
tissue. 
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 To put this all into perspective, a “quality of life” analysis for the cost benefit of 
this new procedure is included. This is done because “quality of life” is the driving force 
behind medicine and the medical profession.  According to a Stanford Economist, the 
average value of human life per year is $129,00028. Assuming that two years is the lowest 
average survival years for any age group, the human quality of life that could be attained 
is equal to $258,000 which is equal to the benefit that the threads provide. 
Comparatively, the cost of the Microthreads with minimally invasive applications would 
be approximately $2,500. The benefits greatly outweigh the cost with a beneficial 
difference of $255,500. 
Table 4: Cost-Benefit Analysis 
Microthread Manufacturing and Use $363
Hospital and Physician Service per Day $624
Endoscopic Procedure $1,398
Total ≈ $2,500
Value Quality Human Life $129,000
x2 (minimal survival years) $258,000
$258,000 - $2500 = $255,500
Benefit
Cost
Benefits greatly outweigh the costs.  
IV.2.2.3 Anticipated Cost of a Microthread 
Using the current production techniques, focusing on the extrusion system and the 
solutions required to create the threads, the manufacturing cost of the threads can be 
approximated.  Baseline costs for equipment and solutions were determined through the 
use of online suppliers.  Most of the extrusion system has a one time use limit, meaning 
the costs will be incurred during each production cycle of the threads (as seen in the 
Table 5). 
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Table 5: Microthread Pricing 
1mL syringe $0.16
Surgical Tubing $0.11
1xDMEM $0.04
HEPES Buffer Solution (1 M) $13.81
Pay for Work Study Student (8hrs) $72.00
Total w/out Collagen and Cells $86.12
Price per Thread without Collagen and Cells
 
Based on the findings and assumptions provided in Table 5, the extrusion system 
costs will be approximately $86 per use. The cost of collagen and seed cells is not 
included in this analysis since price varies greatly depending on the type of collagen 
used, the vendor company, and the size of the Microthread batch.  The price of collagen 
products ranges from $231.00/0.5mg (Bovine Collagen Type III) to $525.00/0.5mg 
(Human Collagen Type IV)29. The cost of seed cells (mesenchymal stem cells) poses 
another pricing challenge, because the specific methods necessary to prepare the patient’s 
cells (separate basal cells into the hMSCs) for this therapy is unknown. 
IV.2.2.4 Cost Reduction Strategies 
 
 Microthreads have the potential to greatly reduce costs associated with the 
treatment of myocardial infarctions (MI).  The cost benefits will be seen by insurance 
companies, hospitals, physicians, patients and society in general.  The minimally invasive 
nature of the procedures ultimately envisioned for the application of Microthread 
therapies will limit the duration of hospital visits for treatment.  This will, in turn, reduce 
the overall cost of the treatment and allow the patent to resume normal daily functions 
sooner.   
Microthread therapies will be administered on an outpatient basis that should be 
completed in one day. At a cost of approximately $624/day for a hospital visit with 
physician services26 included, the possible cost savings become obvious.   Since the use 
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of Microthread technology would require a significantly reduced medical follow-up, 
months rather than years, further cost saving/avoidance would be anticipated.  
 The current theory that Microthreads, seeded with hMSCs will regenerate 
infarcted tissue, will lead to less time needed for cardiac rehabilitation. The patients 
would likely feel better faster enhancing their desire to work on strengthening their heart, 
expediting the healing process. Bodo E. Strauer et al conducted an experiment comparing 
the effectiveness of delivering bone marrow cells to an infarcted area along with cardiac 
rehabilitation versus standard protocol and rehabilitation. The patients who received the 
regenerative cells and therapy completed the entire rehabilitation course in three months 
with significant improvement to their infarcts; while their controlled counterparts 
remained in rehabilitation for six months with no infarct improvement30.  
 While this will likely result in a higher rate of patients utilizing and completing 
cardiac rehabilitation programs (cost to insurers and patients will be higher) the overall 
cost for rehabilitation will be lower because treatment time will be significantly reduced.   
 As seen in Table 6, Microthreads will also be less costly then the other competing 
technologies currently on the market or under development. With the known 
manufacturing costs, Microthreads can be produced and utilized for less than its primary 
competitor, the heart patch. While synthetic threads, intravenous and direct injection 
therapies have lower manufacturing cost, the effectiveness of those treatments are 
significantly less than the effectiveness of Microthreads  technology (refer to Section 
III.4 of this report).  
 
 
 47
 
Table 6: Competition Costs 
Microthreads > $363
Direct Injection Minimal
Heart Patch $500 - $1000
Intravenous Minimal
Stents $52,930
Synthetic Threads $36
Medicinal $363
Cost to Manufacture and Utilize
 
 
The cost of producing the Microthreads is likely to decrease as use of the technology 
grows and the manufacturing processes are streamlined. 
IV.2.2.5 Economic Factors 
 From an economics standpoint, Microthreads have a good chance of success. 
There are currently no true alternates for this technology on the market, although there 
are competitors that currently aim to treat infarcted heart tissue.  Microthread technology 
can be considered to compliment many medical treatments currently in use and/or 
proposed for use.  
The patient’s perceived “willingness to pay” figures greatly into the overall 
economic value of this technology.  The behavioral economic prospective theory shows 
that if one were to gauge a person’s reaction to the resultant lose or gain from the same 
reference point; loss is far more emotionally devastating than the emotional reward from 
the gain. This is relevant to Microthreads because the devastation of losing heart function 
will, most likely, outweigh the emotional loss associated with losing a small sum of 
money, increasing the patient’s willingness to pay for a desirable solution. 
 The supply and demand curves (Figure 10) for this product show cost will remain 
relatively constant.  This is due to the fact that as time goes by the manufacturing process 
will be streamlined, allowing the threads to be produced in a higher volume and a lower 
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cost. This will cause the supply curve to shift to the right. As Microthreads infiltrate the 
market, their benefit is likely to be seen and demand will increase for the threads as well. 
This will cause the demand curve to shift to the right as well.   
 
Figure 10: Supply-Demand Curves of Microthreads 
 
IV.2.2.6  Break-Even Point 
 
 An analysis was conducted to determine the break-even point for this 
product to gage the value of pursing the development of this technology from a financial 
standpoint. The analysis was accomplished based on assumptions derived from the cost 
section of this report.  The first break-even point was based on licensing Microthreads to 
other researchers. The numbers were then calculated as shown below: 
 
Price 
Quantity 
Demand 1 Demand 2 
Supply 2 Supply 1 
Cost 
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Variable Cost per Unit
Extrusion System $14.12 / 10 units = $1
Direct Labor $72 / 10 units = $7
Total = $8
Fixed Cost
Development Costs $1,000,000
Expected Sales 10,000 units
Price per Unit $300
Total Revenue $3,000,000
Total Variable Costs $80,000
Total Profit $1,920,000  
 
Calculating the total cost and total revenue for the number of units produced in 
increments of 500, it was found that the hypothetical break-even point is at 3500 units of 
Microthreads.  
Table 7: Break-Even Profit Preliminary 
Units Fixed Cost Total Cost Total Revenue Profit 
0 $1,000.00  $1,000.00  $0.00  ($1,000.00) 
500 $1,000.00  $1,004.00  $150.00  ($854.00) 
1000 $1,000.00  $1,008.00  $300.00  ($708.00) 
1500 $1,000.00  $1,012.00  $450.00  ($562.00) 
2000 $1,000.00  $1,016.00  $600.00  ($416.00) 
2500 $1,000.00  $1,020.00  $750.00  ($270.00) 
3000 $1,000.00  $1,024.00  $900.00  ($124.00) 
3500 $1,000.00  $1,028.00  $1,050.00  $22.00  
4000 $1,000.00  $1,032.00  $1,200.00  $168.00  
4500 $1,000.00  $1,036.00  $1,350.00  $314.00  
5000 $1,000.00  $1,040.00  $1,500.00  $460.00  
5500 $1,000.00  $1,044.00  $1,650.00  $606.00  
6000 $1,000.00  $1,048.00  $1,800.00  $752.00  
6500 $1,000.00  $1,052.00  $1,950.00  $898.00  
7000 $1,000.00  $1,056.00  $2,100.00  $1,044.00  
7500 $1,000.00  $1,060.00  $2,250.00  $1,190.00  
8000 $1,000.00  $1,064.00  $2,400.00  $1,336.00  
8500 $1,000.00  $1,068.00  $2,550.00  $1,482.00  
9000 $1,000.00  $1,072.00  $2,700.00  $1,628.00  
9500 $1,000.00  $1,076.00  $2,850.00  $1,774.00  
10000 $1,000.00  $1,080.00  $3,000.00  $1,920.00  
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The second break-even analysis takes clinical trials into account. The numbers were then 
calculated as shown below: 
Variable Cost per Unit
Extrusion System $14.12 / 10 units = $1
Direct Labor $72 / 10 units = $7
Total = $8
Fixed Cost
Development Costs $51,000,000
Expected Sales 200,000 units
Price per Unit $300
Total Revenue $72,600,000
Total Variable Costs $1,600,000
Total Profit
$20,000,000  
 
Calculating the total cost and total revenue for the number of units produced in 
increments of 500, it was found that this hypothetical break-even point is approximately 
150,000 units of Microthreads31.  
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Table 6: Break-Even Profit with Clinical Trials 
Units Fixed Cost Total Cost Total Revenue Profit
0 $51,000.00 $51,000.00 $0.00 ($51,000.00)
10000 $51,000.00 $51,080.00 $3,630.00 ($47,450.00)
20000 $51,000.00 $51,160.00 $7,260.00 ($43,900.00)
30000 $51,000.00 $51,240.00 $10,890.00 ($40,350.00)
40000 $51,000.00 $51,320.00 $14,520.00 ($36,800.00)
50000 $51,000.00 $51,400.00 $18,150.00 ($33,250.00)
60000 $51,000.00 $51,480.00 $21,780.00 ($29,700.00)
70000 $51,000.00 $51,560.00 $25,410.00 ($26,150.00)
80000 $51,000.00 $51,640.00 $29,040.00 ($22,600.00)
90000 $51,000.00 $51,720.00 $32,670.00 ($19,050.00)
100000 $51,000.00 $51,800.00 $36,300.00 ($15,500.00)
110000 $51,000.00 $51,880.00 $39,930.00 ($11,950.00)
120000 $51,000.00 $51,960.00 $43,560.00 ($8,400.00)
130000 $51,000.00 $52,040.00 $47,190.00 ($4,850.00)
140000 $51,000.00 $52,120.00 $50,820.00 ($1,300.00)
150000 $51,000.00 $52,200.00 $54,450.00 $2,250.00
160000 $51,000.00 $52,280.00 $58,080.00 $5,800.00
170000 $51,000.00 $52,360.00 $61,710.00 $9,350.00
180000 $51,000.00 $52,440.00 $65,340.00 $12,900.00
190000 $51,000.00 $52,520.00 $68,970.00 $16,450.00
200000 $51,000.00 $52,600.00 $72,600.00 $20,000.00  
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IV.2.3 Strength, Weakness, Opportunity & Threat (SWOT) Analysis 
 
  
• Changes in FDA regulations 
• Changes HCPCS codes 
• Competitors creating a substitute for 
Microthreads 
• Lack of funding 
• Unforeseen issues due to unknowns 
• Ripe market, in need of new 
technology/treatments 
• Competitors only focus on one delivery 
system and deliver cells in similar 
fashions 
• Competitors not as precise as Microthreads 
• Can be used as more than just a thread; can 
be used to create living patches 
• Has future potential as a platform technology 
in other areas 
• Good local for clinical testing and launching 
into market 
• Heart market remaining strong and need is 
increasing for solution 
• Many unknowns at this point in time 
      - How large of an infarct can it repair? 
      - How well will it work minimally 
invasively? 
      - Will it create scar-pulling around 
sutures? 
      - Will there be an immunoresponse? 
• Not enough current funding 
• Requires more being done on research and 
marketing simultaneously 
• No milestone breakdown 
 
• Delivers cells directly to affected area 
• Made of naturally occurring proteins; will be 
compatible with human bodies 
• Biodegradable 
• Treats cause of the disease rather than the 
effects 
• Regenerates dead tissue 
• Cells can be taken directly from patient; 
autologous 
• Very large market 
• High potential for minimally invasive 
procedures in addition to surgical use 
• Nothing else like it on market or in 
development 
• Improve the quality of patients’ lives 
 
Strengths 
Threats Opportunities 
Weaknesses 
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IV.3 MARKET POSTION EVALUATION 
IV.3.1  Myocardial Infarction Market Size 
 
 The previous sections gave a high level overview of the potential market for 
myocardial infarctions. With a current population of 8.1 million people having suffered a 
MI, 7.9 million survivors, 600,000 more people entering the market each year and 
320,000 people suffering from recurrent attacks4, the myocardial infarction market 
provides a solid niche for Microthread technology. While myocardial infarctions do result 
in death, the total number of those who have perished due to the infarction pales in 
comparison to the patients who survive with the damaged tissue.  Figure 11 illustrates the 
potential market size (and need for an effective treatment) based on a breakdown, by 
percentage, of the myocardial market demographics 
Previous MI
87%
New MI
7%
Recurring 
MI
4%
Death MI
2%
 
Figure 11: Myocardial Market 
 
Death due to MI is only two percent of the market.  This indicates a potential market 
population of 98% that can benefit from the application and use of Microthread 
technology. 
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IV.3.2 Competition 
IV.3.2.1 Injection Method 
 
 Currently, there are three competing methods that support direct injection of 
therapeutic agents or cells into an infarction or into the surrounding tissue.  These include 
direct intracadiac injection, injection during surgery, and the developmental robotic 
HeartLander. 
 The favored method of delivering therapeutic cells is via intracardiac injection, a 
technique derived from the emergency medical practice of delivering epinephrine to a 
seizing heart. Intracardiac injection accesses the heart directly through the skin utilizing a 
needle inserted through the myocardium and into a cardiac chamber. This is performed 
through one of two standard injection techniques that allow direct access to the heart 
shown in Figure 1232. 
 
Figure 12: Intracardiac Injection32 
Subxiphoid approach, needle is inserted 1cm to the left of the xiphoid process and aimed toward the left 
shoulder. The locations for the parasternal approach are indicated by the red x’s. 
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The intracardiac injection method is simple, quick and minimally invasive. This 
procedure utilizes current practices, techniques and technologies to deliver therapeutic 
cells directly to the infarcted areas of the heart. The needle and syringe are inexpensive 
and lead to an outpatient procedure. The therapeutic cells that are delivered to the heart 
can be autologous. Studies have shown a success rate of 11% of the total cells injected 
engrafting to the heart wall33.  
 There are drawbacks to this method of delivering therapeutic cells. The potential 
complications that a patient may experience from the injection itself include the 
following: pneumothorax (collapsed lung), coronary artery laceration, myocardial 
laceration, hemopericardium (blood in the pericardial cavity caused by atrium or 
coronary artery rupture or the perforation of a ventricle), and perforation of the stomach 
or liver. It has also been associated with inducing intractable ventricular fibrillation30. 
While using a smaller spinal needle and the subxiphoid method has minimized these 
complications, they are still a prevalent problem with this procedure. The insertion of the 
needle into the thoracic cavity can be quite painful and the adherence of the cells to the 
heart wall is not assured. After the needle is removed, cells are pumped out through the 
puncture hole or into circulation, and there is no way to control cell growth and 
attachment34.  
 The second type of injection occurs during open heart surgery. Unlike its 
minimally invasive counterpart, this method is utilized as an additional procedure that 
can help improve heart function. In this case, the surgeon is able to directly inject cells 
into the infarcted area due to the access that open heart surgery allows.  
 56
 Since this is an additional procedure that employs common techniques and tools 
that are relatively inexpensive, it is safe to assume that the cost of the supplementary 
method will be minimal. The therapeutic cells utilized can be autologous and the success 
rate of this method is the same as stated above with the intracardiac injection process. 
The drawback to this technique is that as an additional procedure and with a success rate 
that is relatively low, surgeons may feel that it is not worth including this practice in the 
surgery.  
 The third method is currently in animal testing and utilizes a robotic device to 
inject therapeutic cells into the heart. This device is known as the HeartLander, an 
inchworm-like robot that can navigate around the exterior of the heart. This crawling 
robot consists of a front and rear body section attached to a flexible tether line which the 
body pieces glide along to induce movement35. The tether connects the HeartLander to 
tabletop instrumentation that supports the various device functions. Three wires pass 
through the center of the tether which is connected to an exterior motor that creates 
locomotion. A vacuum line creates suction that allows for the HeartLander to move by 
alternating the suction between the body sections. The vacuum pressure is monitored by 
pressure sensors and is regulated by computer controlled valves. This series of balances 
ensures that the heart tissue is not damaged by the suction force of the device. There is 
also an optic endoscope that runs through the tether line and is attached to a computer for 
visual feedback.  
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Figure 13: Design of HeartLander36 
Picture Courtesy of Carnegie Mellon Robotics Institute 
 
 In a retracted state, the robot is 17.7mm (length) x 8.2mm (width) x 6.5mm 
(height). The length changes as the robot makes its way along the heart due to the 
retracting and extending of the device’s locomotion. The HeartLander has a 1mm 
diameter needle channel and a 2mm diameter working port where tools can be deployed 
to rectify a variety of heart procedures. For myocardial injection applications, a surgeon 
would advance a needle by hand through the 1mm needle channel and into the infarcted 
tissue. The surgeon would judge the depth of the puncture by textile sensation and 
through the visualization provided by the HeartLander technology. The cells would be 
injected through a syringe located on the exterior portion of the needle35.  
 
Figure 14: HeartLander and placement on heart36 
Picture Courtesy of the Carnegie Mellon Robotics Institute 
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 The crawling robot is placed upon the heart by creating an incision below the 
sternum and inserting the HeartLander into the thoracic cavity using the subxiphoid 
approach shown in Figure 14. Once that step is completed, a second incision is made in 
the pericardium. The HeartLander is inserted into the slit and is put directly on the 
exterior surface of the heart under the pericardium layer. The robot can then crawl over 
the heart through the use of alternating suction to the front and rear body sections. The 
distance between the body sections is created by an external actuator that pushes and 
pulls upon the tether of the HeartLander37.  
 The therapeutic robot is controlled by a doctor using a joystick and a computer 
program directly linked to the HeartLander to show the exact location of the technology 
on the heart. A tracking sensor located on the front body of the robot allows for the real 
time location of the droid to be displayed on the computer screen at all times37.  
 In vivo testing has been performed in porcine subjects. These studies have shown 
that the subxiphoid approach is safe for the subjects and has proven the locomotive 
abilities of the device. During these tests, it was demonstrated that the HeartLander can 
travel along the anterior and lateral surfaces of a beating heart without restriction. The 
tests included forward motion, backward motion and turning. No adverse events were 
noted in the porcine subjects during the trials. After the tests the procine hearts were 
excised and no epicardial damage was found35,37.  
 The HeartLander is constructed out of disposable materials that can be hooked up 
to tabletop instrumentation to be utilized. This allows for the individual units to be 
replaced for each patient’s surgery. The real-time visualization of the heart with the 
tracking sensor allows for the surgeon to guide the technology to the exact location they 
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wish to deliver therapeutic cells. In addition to repairing infarcted heart tissue, this device 
was created with the objective to improve minimally invasive surgery. The 2mm 
diameter working tool port can allow the HeartLander to perform a multitude of surgeries 
once the technology is perfected further.  
 While exact pricing is not available, it can be assumed that this technology will be 
costly to use. Even though the HeartLander itself is disposable, the equipment that it is 
attached to and the procedure that is used will increase the overall cost. It is highly 
probable that there will be the cost of additional personnel to monitor and run this 
equipment.  Additionally, the software that will be needed to visualize the 3-D model of 
the heart will be expensive. 
 Another issue deals with the injection of the therapeutic treatments. As with the 
other direct injection methods, there is no way to anchor the cells to the affected area. 
Also, while the surgeons control the depth of the insertion of the needle within the 
cardiac tissue, testing with dye has revealed that the injection depths averaged from three 
to five millimeters. 
  
Figure 15: HeartLander CMU test results36 
Photos Courtesy of the Carnegie Mellon Robotics Institute 
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If the injection depth is not increased, then it is possible that the infarcted tissue may not 
be reached. The dye and cell delivery has not been tested in an environment with 
necrosed tissue yet, so definitive proof is not available.  
 While all three of these direct injection methods offer unique advantages to the 
application of cells to damaged heart tissue, every one of the procedures encounter a 
similar problem:  there is no way to anchor the therapeutic agents and cells to the 
infarcted areas being treated.  After cells are injected into the heart and the needle is 
removed, the majority of the cells are pumped out of the heart into the blood stream.  
These methods offer no mechanism to control the cells once they are injected into the 
heart muscle.  
IV.3.2.2 Heart Patch 
 
 Heart patches are intended to replace missing and damaged heart tissue. A heart 
patch is a 3-D scaffold constructed out of synthetic or biologically-derived materials upon 
which cells are seeded. The scaffolding provides a temporary biomechanical structure for 
the seeded cells until they are able to produce their own sustainable extracellular matrix. 
There have been experiments proving that heart patches are feasible although there has 
yet to be a patch created thicker than one centimeter38.  
 
Figure 16: Heart Patch39 
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 The patch scaffolds can be created for any size, shape, strength and composition 
that are needed to repair the infarcted tissue38. This permits the researchers to construct 
heart patches for a patient’s specific needs. These scaffolds can be seeded with 
autologous cells which is expected to lower the chance of immunoresponse. The tissue 
that is created with the scaffolds is intended to function as normal heart tissue. This can 
completely resolve the issue of infarcted and damaged heart tissue by replacing it with 
healthy, fully functional tissue. Shimizu et al grew rat cardiomyocytes on polymer 
scaffolds that created thin layers of cells in the form of sheets. Researchers placed four of 
the cell sheets on top of each other until they fused, and then implanted the fused sheets 
under the skin of rats for a period of six months. After the six month period, researchers 
discovered that the heart patch was beating and had been infiltrated with host blood 
vessels40. Zimmerman et al have demonstrated in their experiments that a similar heart 
patch survives at least 28 days after transplantation into a rat’s heart41. 
 In order for the heart patch to be administered, a patient must undergo open heart 
surgery. This means the same effects as mentioned in the open heart surgery section 
apply to this area, as well as potential complications that may come to light as the 
technology is further developed. Since the damaged tissue is removed and replaced with 
the patch the chance for complications are increased. The total costs of the procedure will 
most likely be very expensive. One heart patch scaffold without cells ranges from $500 to 
$1000 depending on the size and composition of the patch20.    
IV.3.2.3 Intravenous Delivery 
 
 Intravenously introducing cells into the body is done through an intravenous (IV) 
drip. The drip delivers the treatment via a needle in the patient’s radial vein. The needle is 
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attached to a plastic tube with a regulator which comes down from a bag that is filled 
with the fluid used to treat a patient. For cardiac regeneration, a high concentration of 
cells is introduced to the patient’s body through the IV drip. The cells then travel through 
the bloodstream to affected area in the heart. 
 
Figure 16: IV drip42 
 
 This method is the most minimally invasive of all the competition. Costs will be 
minimal since this procedure utilizes a current method for delivering fluids into the body 
and is an in-out procedure. The cells delivered in the therapeutic solution can be 
autologous to help minimize any immunoresponse. It has been shown in a study by 
Matthew Pricea that this method also begins to repair tissue in small clusters. However, 
the same study demonstrated the dangers of this method. Matthew Price and Chung-
Chuan Chou found in testing the IV delivery of MSCs to a damaged pig heart that the 
therapeutic cells attached to and grew in the lungs. The post-mortem examination of the 
porcine subject revealed “a large bolus of cells in the lung vasculature43”, which can 
create complications. This is caused by the way the therapy enters the body. Since the 
cells are dripped directly into the bloodstream, the therapeutic cells pass through the 
lungs and other organs prior to and after passing through the heart. There are no signaling 
factors that allow the physicians to control where the cells will attach within the body. It 
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has been found that less than one percent of the therapeutic cells injected into a patient 
with this method will attach to the heart wall44. 
IV.3.2.4 Balloon Stents 
 
 Stents are used to hold blocked arteries open and increase blood-flow to the heart. 
Made from tubular meshed wire metal, the stents are collapsed and placed over a balloon 
catheter. A separate balloon catheter is then inserted into an artery (near the groin, arm or 
wrist) and advanced towards the heart45,46. A series of x-rays are taken to visualize the 
clogged heart artery while the balloon catheter is advanced into the heart. Once the 
catheter-stent reaches the area of blockage, the balloon is inflated and deflated several 
times to drive the plaque build-up against the arterial wall. The catheter is then removed 
and the catheter-stent is moved to the afflicted area. When the area has been reached, the 
second balloon is inflated, expanding the stent which locks in place that forms a scaffold 
and holds the artery open. The stent stays in the artery permanently and the balloon 
catheter is removed from the body. The wire stent will be covered in a thin layer of 
endothelium as the body adjusts45,46.  
 
Figure 17: Balloon Catheter and Stent Deployed47 
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 A recent modification to stents was the addition of a medicated layer on the outer 
surface of the stent. This medicated layer is intended to help reduce inflammation and the 
possibility of restenosis (re-blockage) of the artery. The type of medication on the stent 
varies by the manufacturer, as does the time-release formula of the medication. While a 
medicated stent theoretically can reduce inflammation, additional medications must be 
taken by the patient to aid with the healing process. Most patients, whether their stent is 
medicated of not, are prescribed aspirin or Plavix to help reduce the formation of blood 
clots in or around the stent48. 
 Stents are minimally invasive and effectively improves the flow of blood. This 
method is also proven to work specifically for improving the blood flow to the heart.
 While stents are capable of bettering the blood flow heart the stents do not have 
the ability to treat infarcted tissue. Stents can be seen as a preventative measure against 
infarcted tissue occurring, but once the tissue has reached that point they cannot reverse 
the damage. Even with the medicated-stents that aid in the repair and health of the 
arteries fails to affect the heart wall itself. If the medicated gel was replaced with a gel of 
hMSCs and placed upon the stent, the cells would have nowhere to go accept the arterial 
wall where they will be unable to repair the infarcted tissue. In addition to these points, 
the cost of stents is very high as well. The entire procedure for fixing two vessels with a 
stent costs approximately $52,930 49. 
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IV.3.2.5 Polymer (Silk) Threads 
 
A good-quality surgical thread has the following characteristics: 
• Is sufficiently strong and reasonably thick 
• Will easily pass through tissue, will not be hung up on tissue particles 
• Flexible, easy to knot without unraveling the thread 
• Will not fray50 
 Synthetic threads can be broken into two main groups: nonabsorbable sutures and 
absorbable sutures. Nonabsorbable sutures were the most common types of threads used 
in surgery until the recent developments with biodegradable synthetics and are still used 
on topical wounds. The most prominent nonabsorbable suture is silk thread. 25ft of 
0.08mm thick silk surgical thread runs at $35.8050 per roll. There are various absorbable 
sutures available on the market currently, the most common include: polyglycolic acid 
sutures, polyglactin 910 sutures, chromic catgut sutures, plain catgut sutures, 
polydioxanone sutures and poliglecaprone 25 sutures52. Exact prices for the absorbable 
threads are unknown since many are new to the market.  
 Synthetic threads have been used for many years to effectively sew tissue 
together. The biodegradable threads offer an additional benefit that as the wound heals; 
the suture will dissolve over time eliminating the need to remove the threads. However, 
even with biodegradable threads, synthetic threads are not the ideal material to place in 
the body. Any foreign object placed in the body can induce an immunoresponse and will 
not necessarily aid in the healing process. Another key point is that the surgical threads 
can not necessarily be seeded with cells. The synthetic materials from which the synthetic 
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threads are constructed are not capable of sustaining cell life and may be cytotoxic to the 
cells.  
 Researchers at University College London in the United Kingdom have created 
“microthreads from polymers containing living cells, using a technique called 
electrospinning. These biologically active threads could be formed into medical scaffolds, 
to deliver cells directly to tissue and promote healing.53” The United Kingdom 
researchers utilize synthetic materials and electrospinning to create a different type of 
“thread”54. The actual product of electrospinning is a very fine network of nets and webs 
that have no order or organization. Along with synthetic materials, therapeutic cells have 
been introduced into the mixture as well, creating a spun network of webbing and cells. 
This network of nets and webbing is approximately 1000 times smaller than that of the 
WPI Microthread technology, making it near impossible to utilize as a surgical thread 
(invisible to the naked eye)21. This small diameter also violates the first principle of a 
good-quality thread, which requires a thread to be reasonably strong and thick. 
IV.3.2.6 Current Medicinal Treatments 
 
 The purpose of medication is to make the patient feel better in the short and long 
run. Heart medications are used to help patients live longer, have fewer symptoms, ease 
breathing, increase activity levels, reduce swelling and keep them out of the hospital. To 
control the various symptoms that occur after a heart attack, most patients will be 
prescribed several different heart medications. While there are a variety of heart 
medications, the most common types of heart medications are: ACE (angiotensin-
converting enzyme) inhibitors, beta-blockers, digoxin, diuretics, aldosterone antagonists, 
and isosorbide dinitrate/hydralazine55. 
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Angiotensin-Converting Enzyme (ACE) Inhibitors 
 ACE Inhibitors treat high blood pressure by blocking an enzyme that leads 
to the release of a substance called angiotensin (which causes blood vessels to 
constrict). ACEIs relax blood vessels throughout the body which lowers blood 
pressure, thereby reducing strain on the heart56,57. In 2004, ACEIs were the third 
most widely prescribed class of medicines for heart failure. There is a substitute 
for ACEIs known as an angiotensin receptor blocker (ARBs) for patients who 
react adversely to ACEIs58. The benefits and side effects are the same; ARBs 
block angiotensin in a different manner. Side effects of ACEIs and ARBs include: 
lose of potassium, dizziness, fever and chills, hoarse throat, swelling in 
extremities, trouble swallowing or breathing, abdominal or chest pain, jaundice, 
skin rash, joint pain, light-headedness, fainting, nausea, vomiting, numbness, 
confusion, persistent dry cough, fatigue and headaches57. 
Beta-blockers 
 Beta-blockers treat high-blood pressure by blocking adrenaline. 
Adrenaline increases heart rate, causing the heart muscle to contract more 
strongly, and constricts arteries throughout; which causes blood pressure to rise56. 
By blocking adrenaline, the beta-blockers decrease the heart rate and reduce the 
strain put on the muscle, thereby decreasing blood pressure. It has been found that 
if a patient takes a beta-blocker after a heart attack, their risk of a repeated attack 
and death is lowered by 15% to 25%59. Beta-blockers have become a standard of 
medicinal therapy for infarction patients. Side effects include: decreased blood 
circulation, sensitivity to sunlight, dizziness, light-headedness, fainting, fatigue, 
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weakness, depression, difficulty breathing, joint swelling, nausea, vomiting, 
anxiety, dry eyes, fever and numbness of skin56.  
Digoxin 
 Digoxin, also known as digitalis, is a drug that is derived from the leaves 
of the foxglove plant. It improves heart function by correcting hormonal 
imbalances that worsens heart failure, strengthening the healthy tissue and the 
heart beats stronger and with a more regular rhythm. Since digoxin increases the 
strength of the heart beat, the flow of blood and oxygen throughout the patient’s 
heart is increased as well; making it easier for the patient to breathe and helping 
him/her to feel better59, 60. Digoxin is one of the top prescribed medicines for 
patients who have suffered a heart attack since it improves the overall pumping 
capabilities of the damaged heart. Side effects of digoxin include: nausea or 
vomiting, blurred or colored vision, hallucinations, confusion, dizziness, rashes, 
enlarged breasts (men) or headaches56.  
Diuretics 
 Diuretics help the body to rid itself of excess water and salt through urine. 
Releasing the excess fluid causes blood pressure to lower and the strain placed 
upon the heart to decrease. Diuretics also help alleviate pressure on the lungs and 
decreases swelling in a patient’s joints. Some diuretics can create potassium lose 
within the body, making it important to monitor a patient’s potassium levels while 
on this drug. Side effects include: dizziness, light-headedness, dryness of mouth, 
irregular heartbeat, mood swings, nausea, vomiting, weakness, fatigue and 
weakened pulse56.  
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Aldosterone Antagonist 
 Aldsosterone antagonists help to block the effects of the harmful stress 
hormone aldosterone. If the aldosterone hormonal level is elevated, it can result in 
high blood pressure as well as increased water and sodium retention in the body. 
Side effects include: breast enlargement or tenderness (particularly in men) and 
increased potassium levels56, 58.  
Isosorbide Dinitrate 
 Isosorbide dinitrate relaxes the blood vessels, allowing them to widen and 
increases the blood flow. The increased blood flow reduces the amount of work 
on the heart, reducing the oxygen needs of the heart and minimizes chest pain. 
Side effects include: dizziness, light-headedness, headache, fainting, nausea, 
vomiting and irregular heartbeat56. 
Hydralazine  
 Hydralazine is used to treat patients with severe high blood pressure when 
it is urgent to lower blood pressure. This medication relaxes and dilates the blood 
vessels, allowing for a better blood flow. Side effects include: diarrhea, appetite 
loss, headache, nausea, vomiting, chest pain, difficultly breathing, fatigue, 
weakness, numbness, fever, chills and irregular heartbeat56.  
 
 Medicinal treatments are effective at alleviating the symptoms after a heart attack. 
This method is non-invasive since medicine is taken orally. The cost of the medication 
can become rather expensive since most medications need to be taken for the rest of the 
patient’s life. However, the costs are heavily dependant on what types and combination 
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of drugs the physician prescribes. A drawback to this treatment is that it treats only the 
symptoms and it does not eliminate the cause. 
IV.3.2.7 Microthreads versus the Competition 
 
 In order to compare and contrast Microthreads against the competition, a 
weighted matrix (Table 8) was developed by the author to rank important attributes of the 
various cardiac repair devices and procedures in an unbiased manner.  The capabilities of 
each technology was written on a piece of paper and ranked without any association to 
the device it belonged to. The ratings were then collected and divided back into the 
technologies that they all belong to. Microthreads and competing technologies are 
compared based on a list of beneficial attributes provided in the first column. The matrix 
also provides the total attribute value scale and assigns a benefit value for each device 
based on research.  The highest Total Values and Percentages indicate the “best” 
treatment based on available data.  
Table 8: Microthreads - Competition Comparison 
Potential 
Total
Microthreads Heart Patch IV Direct Injection Medication Stents Polymer Threads
Minimally Invasive 5 4 1 4.5 4 5 4 3
Biocompatiblity 5 5 5 4 4 3 3 3
Cost 5 3 2 4 4 3 2 3
Localized Delivery of Cells 5 5 5 1 2 0 0 2
Repair Infarcted Tissue 5 4.5 4.5 2 2 0 0 1
Minimal Side Effects 5 4.5 3 1 1 3 3 3
FDA Approval 3 2 2 3 3 3 3 3
Future Potential 5 4.5 4 1 2 3 2 2
Clinical Trials 5 2 2 4 3 4.5 4.5 4
# of Unknowns 5 1 1 4 3 4 4 3
Insurance Coverage 3 2 2 3 2 3 3 3
Benefits to MI Patients 5 5 4 2 2 2 2 2
Low Chance of Immunoresponse 5 5 4 2 2 2 2 2
Totals 61 47.5 39.5 35.5 34 35.5 32.5 34
Total Percentage 78% 65% 58% 56% 58% 53% 56%
 
5 excellent
4 above average
3 average
2 fair
1 poor
0 N/A
Key
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Table 8 and Figure 19 indicate that Microthread technology is the most attractive choice 
for cardiac treatment. It was closely followed by the heart patch and the other five 
products fell into roughly the same categories. It should be noted, that current medicinal 
treatment still performed well enough to top three of the other competitors.  This shows 
that medicine is still a strong competitor, despite the fact that it provides no appreciable 
benefit in the categories of repair of infarcted tissue and delivery of cell therapy. 
  
 
 
Figure 18: Competition Comparison Venn Diagram 
 
 Microthread technology has the ability to work with its competing technologies. 
Devices such as the HeartLander and the heart patch could benefit from a partnership 
with Microthreads. With the HeartLander, the Microthreads could be sutured directly into 
the infarcted tissue via the HeartLander’s needle channel (combining the strengths of the 
two technologies). The heart patch could benefit in an alternative way. Microthreads 
could be used to suture in the heart patch once the infarcted tissue is removed. This 
Minimally Invasive Effectiveness 
Microthreads 
Direct Injection 
Intravenous 
Stents 
Heart Patch 
Medication 
Polymer Threads 
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would promote healing around the seam of the heart patch, making the patient healthier 
faster.   
IV.3.3  Marketing Microthread Technology 
Patients’ Views: 
 The patient’s views of Microthreads and their potential benefits are very 
important to the success of the technology. It will be essential to emphasize how a patient 
will benefit from the Microthread therapies and how it is different from other available 
treatments. Rehabilitation programs will be crucial in the patient’s return to full health 
after receiving Microthread treatments. However, rehabilitation is just as important for 
cardiac patients today. Yet it remains a very under-utilize resource. How will patients be 
motivated differently with the Microthreads? The answer is simple; Microthread 
therapies add a dimension of hope that is missing with current technology.  Instead of 
learning how to function with a damaged heart, patients will be strengthening a heart with 
regenerated cells that closely match pre-infarction capability. This knowledge may 
motivate people to attend rehabilitation sessions.  
 Patients will still be prone to depression and other psychological post-myocardial 
infarction symptoms, but it is possible that the promise of improved heart function and 
vitality through the use of Microthread therapy can alleviate the severity of these 
emotions.  The knowledge that the heart can be returned to a fully functional state 
without the need for an intensive surgery may ease patient anxiety and fear.  Overall the 
stress upon patients, their families and loved ones will be greatly reduced because the 
procedure is minimally invasive; and not as intimidating as major surgery. 
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Advancement: 
 Microthreads technology must continue to be advanced from its current point.  
The inventor(s) should seek out and secure help and guidance from experts in the field of 
endoscopy (ensure the proper legal paperwork is in place to protect the proprietary nature 
of any research and inventions).  These experts will aid with the development a device 
specifically designed to locate and implant Microthreads in the heart muscle. This would 
ensure the threads to be delivered in the most effective manner, tailored to the threads’ 
specific requirements.  
 Microthreads currently have to be manufactured in a laboratory environment to 
strict standards including sterility. Because of the necessary manufacturing processes 
involved in creating threads, there is a heightened risk for contamination.  Therefore, 
production must be improved and streamlined so that it can occur in a sterile 
environment. Once an appropriate Microthreads production methodology is developed, 
hospital staff, biomedical engineers and other health professionals must be trained in the 
methods.  In the future, off-site (vendor based) bioreactors will allow for Microthreads to 
be manufactured in one centralized location and delivered directly to hospitals and other 
end users (i.e.: cardiologists, etc.).  
IV.3.4  Licensing versus Starting a Business 
 Starting a business is an immense undertaking and has potential to be difficult for 
the co-inventors of this product at this time as they are all employed professors at 
Worcester Polytechnic Institute; though such a path is feasible if the creators so choose.  
Pursuing further development and funding for Microthread technology, as outlined 
earlier, would require significant effort. While they could choose to start one of the 
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following types of businesses: General Partnership, Limited Partnership, Limited 
Liability Partnership or a Limited Liability Corporation, it is this author’s opinion that 
none of those options are optimal for the development of their technology.   
It is this author’s opinion that licensing the product information would be a more 
judicious approach to leveraging financial gain from this technology.  A licensing is an 
agreement which allows a second party the use of intellectual property in the way that is 
stated in the licensing conditions, while leaving ownership of the intellectual property in 
the hands of the inventor(s). This would allow the professor(s) to further develop the 
product and bring useful technology to the market. 
If the creators choose to go this route, it would be wise to inform the other 
professionals of this technology. An effective way to introduce Microthreads to medical 
professionals would be for the inventor(s) to prepare a series of informative articles that 
will be submitted to medical journals for publication (for example: Circulation, the 
American Heart Associations Journal). Since the President of the United States has 
signed has an executive order lifting the ban on federal funding for embryonic stem cell 
research, there are likely to be many researchers outside the scope of this project 
searching for ways to deliver these cells into the body. Microthread technology has 
potential to be the scaffold for other researchers to carry out their studies with the 
embryonic cells in addition to testing other cells that have been found to work similarly. 
This would allow the Microthread technology to be a lucrative vehicle for other 
researchers to accomplish their investigations. 
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IV.3.5 Health Insurance Coverage 
IV.3.5.1 Health Insurance 
 
 Health insurance provides financial support for people affected by illness or 
injury. These policies typically cover doctor appointments, hospital visits to the 
emergency room, hospital stays, medicines, medical procedures as well as other medical 
expenses. Health insurance coverage comes in many forms, from the public health 
insurance of Medicare and Medicaid to group insurance provided by employers to private 
insurance to no insurance at all. Since there are a variety of insurance companies that 
handle health coverage, the policies of each institution offer differ wildly. Variables 
include medical conditions covered, the size of the deductible or co-payment (patient’s 
out-of-pocket expenses), the limits of coverage and the available treatment options.    
IV.3.5.2 Health Insurance Reimbursement 
 
 To be ready to be marketed, a new medical device, pharmaceutical 
product or medical procedure, must qualify for health insurance reimbursement to be 
successful. A product or procedure that receives health insurance reimbursement has a 
proven track record for success.  Reimbursement indicates that the insurance provider, 
allocating the funds, believes that the fee schedule is beneficial to all parties involved in 
the transaction.  A fee schedule is the range of fees a doctor is allowed to charge for a 
procedure utilizing the medical protocols. Any type of life saving surgery qualifies for 
insurance reimbursment62.  
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IV.3.5.3 Qualifying for Health Insurance Reimbursement 
 
 In order to qualify for health insurance reimbursement, there are prerequisites that 
each product or procedure must fulfill. The first requirement is that the device or 
procedure must have FDA approval. Once this is obtained, devices (and not procedures) 
must then be reviewed for a reimbursement code by the Centers for Medicare and 
Medicaid Services (CMS). The reimbursement codes given by the CMS are part of the 
Healthcare Common Procedure Coding System (HCPCS). The HCPCS “was established 
in 1978 to provide a standardized coding system for describing the specific items and 
services provided in the delivery of health care. Such coding is necessary for Medicare, 
Medicaid, and other health insurance programs to ensure that insurance claims are 
processed in an orderly and consistent manner”63.  
 This system is divided into two subsystems known as Level I and Level II. Level I 
HCPCS’ are maintained by the American Medical Association and deal with medical 
procedures and services established by physicians and health care professionals. Level II 
HCPCS’ are completely under the CMS jurisdiction and identifies products, services and 
supplies that are not covered within the first level. Level II codes are then divided into 
National Permanent Level II HCPCS Codes and Temporary Level II HCPCS Codes. The 
National Permanent Level II HCPCS Codes “are for the use of all private and public health 
insurers. Since HCPCS is a national coding system all payers will be represented in the 
Workgroup including representatives from private insurance agencies, the Pricing, Data 
Analysis, and Coding (PDAC), and Medicaid will participate in the workgroup meetings and 
provide input as to what is necessary to meet each party’s program operating needs.64” 
Permanent codes are updated once a year on January 1st. Temporary codes are used at the 
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discretion of the CMS for cases where a permanent code does not exist for a certain 
product or service. These products and services can be given a Temporary code which 
can be utilized by insurance companies until the product is eligible to be considered for 
permanent status at the end of the year. Currently 35% of all HCPCS codes are 
Temporary Level II. 
 A company or individual has the option to submit a code request to the CMS by 
using a standard format which includes: 
§ Cover letter outlining the code request and briefly summarizing why 
the code is needed. 
§ Completely answer all questions located within Alpha-Numeric 
HCPCS Coding Recommendation Format Information Supporting 
Coding Modification Recommendation (see Appendix VIII.17).  
§ FDA approval letter. 
§ Supporting documentation and/or descriptive material to further 
understanding of the medical benefits of the item. 
§ No more than three samples of the product, video tapes or compact discs. 
§ Sign and date every recommendation. 
The entirety of the packet must be less than 40 pages in length and every question in the 
recommendation format must be completely answered (seen in Appedix VIII.17)65. For a 
more complete description of this portion of the process, refer to Appendix VIII.18. 
 It is important to note that these codes do not guarantee that a product or 
procedure will be covered by health insurance companies; they merely allow these 
devices or techniques to have the opportunity to be covered. Once FDA approval and a 
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HCPCS code have been obtained, the health insurance companies will take the device or 
procedure into consideration. At that point the success of the device is based upon the 
coverage of each specific health insurer, which devices the professionals choose to use, if 
the device is effective and if it is more cost effective than other alternatives on the 
market.  
IV.3.6 Food and Drug Administration (FDA) Regulations 
 
 The FDA’s mandate is to protect the public’s health and well being.  It is “the 
authority” in determining whether or not products are safe and effective.  The main role 
of this organization as it pertains to the current point in the Microthreads life cycle is the 
premarket approval process.  The approval process is regulated by subgroups that address 
specific areas within the healthcare spectrum. For Microthreads, jurisdiction will be 
based on whether Microthreads are considered a medical device or a biological product. 
There is no clear-cut method to determine which category this product will fall into based 
upon the information that is made available by the FDA.   However, there are regulations 
for combination biologic devices similar to Microthreads.  Under the Federal Food, Drug 
and Cosmetic Act, Chapter 5, Subsection A, Section 503 (21 USC 353)(g)(1) it is stated 
that the Secretary of the FDA will “assign an agency center to regulate products that 
constitute a combination of a drug, device or biological product. The Secretary shall 
determine the primary mode of action of the combination product66”.   
If the Secretary determines that Microthreads are a device, then the Center for 
Devices and Radiological Health will perform the premarket review on the product; 
whereas if it is ruled to be a biological product then it will be regulated by the Center for 
Biologics Evaluation and Research67. If Microthreads are ruled to be a biological product 
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rather than a device, they will have to go through extensive testing in order to be 
considered for approval.  
 In order to obtain approval, the researcher or organization must first inform the 
FDA of its intended product and the supposed effect of the product, the product must be 
tested in the laboratory and then tested in research animals68. When the product is ready 
to begin the human testing phase, it must receive a special exemption from the FDA 
before the tests begin. The exemption is known as an investigational new drug 
application (IND)68. In this application, the researcher or company must describe how 
they intend to perform the study, what the risks of the study are, and how the patients will 
be protected, and they need to provide data to support the validity of the study. In 
addition to this, the study needs the approval of a review board composed of scientific 
and medical advisors along with consumers. Researchers must also obtain the consent of 
patients participating in the study, and inform them of any risks and benefits that are 
associated with the treatment68.  
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V Conclusion 
 
 Microthreads have a promising future in the cardiac market. With a potential 
market of 7.9 million patients, Microthreads offer unique advantages that no other 
product currently in the market or known-development is capable of. While there is 
competition for the cardiac niche aside from Microthreads, the advantages the threads 
hold are greater than the other products reviewed in this report. The novel idea of treating 
the cause rather than the effect of heart problems is uniquely captured by Microthreads. 
These “living threads” have the potential to regenerate infarcted heart tissue by anchoring 
cells directly to the injured tissue.  In the future this technology will be implanted in 
tissue using minimally invasive procedures similar to cardiac catheterization, endoscopy 
or other specialized medical procedures. The biological nature of the threads, composed 
of naturally occurring proteins from the body as well as the subject’s own mesenchymyl 
stem cells, will enhance the patients’ immunoresponse. If Microthreads can be 
manufactured and utilized for less than $363, in addition to receiving FDA approval and 
a HCPCS code, then they can be very successful in the cardiac market. It is this author’s 
opinion that Microthreads have the potential to greatly benefit cardiac patients and is a 
worthwhile venture to pursue.   
 Analysis has shown that, even with the limited scope of research completed to 
date, that Microthread technology has a promising future.  The inventors of this 
technology should act quickly to seize upon the opportunities identified in this paper to 
promote the use of Microthread technology in research and in the medical industry.  The 
inventors should develop a detailed action plan that includes: publishing informative 
articles in medical periodicals and research journals, a detailed development plan to 
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enhance the manufacture of Microthreads, contact teaching hospitals to determine and 
map out the most appropriate route to clinical trials and investigate potential vendors to 
help in the development of a Microthread delivery system that is minimally invasive. 
 It is critical that the inventors secure legal aid to ensure they are in a position to 
grant licensing rights of this technology to medical professionals, researchers and 
commercial vendors as opportunities present themselves.  This more than anything may 
provide the fastest avenue to success for this new and exciting technology. 
 In conclusion, there is a market of at least 7.9 million patients that can benefit 
from the Microthread technology which offers unique advantages, such as treating the 
cause of the disease and the product’s autologous nature. If the Microthreads can be 
manufactured and utilized for less than $363, and receive FDA approval as well as a 
HCPCS code, then this technology will be successful on the cardiac market. Therefore it 
is this author’s opinion that Microthread technology is worth pursuing further.  
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VII  Glossary 
 
1xDMEM (1X DULBECCO'S MODIFICATION OF EAGLE'S MEDIUM) – A 
concentrated solution of amino acids, vitamins and supplementary components (such as 
salts). 
 
Angiotensin-Converting Enzyme (ACE) Inhibitors - Treat high blood pressure by 
blocking an enzyme that leads to the release of a substance called angiotensin (which 
causes blood vessels to constrict). ACEIs relax blood vessels throughout the body which 
lowers blood pressure, thereby reducing strain on the heart. 
 
American Heart Association (AHA) – National volunteer health agency dedicated to 
ending cardiovascular disease and stroke.  
 
Angiogenesis – The growth of new blood vessels from pre-existing vessels. 
 
Beta-blockers - Treats high-blood pressure by blocking adrenaline, which decreases the 
heart rate, reduces the strain put on the muscle, and decreases blood pressure. 
 
Cardiac Myocyte(s) – Heart muscle cell(s). 
 
Cardiovascular Disease (CVD) – Diseases that affect the heart or arteries. 
 
Collagen – Long, strong, fibrous protein that provides an extracelluar matrix for tissues 
and cells within the body. 
 
Cytotoxic – Cell-killing, toxic to cells. 
 
Digoxin – Improves heart function by correcting hormonal imbalances that worsens heart 
failure, strengthening the healthy tissue and the heart beats stronger and with a more 
regular rhythm 
 
Endocardium – Layer of tissue that lines the inner chambers of the heart. 
 
Epicardium – Outer layer of heart tissue, functions as a protective layer around the heart. 
 
Food and Drug Administration (FDA) – Consumer protection agency focuses on 
monitoring products to protect the general public.  
 
Fibrin – Fibrous protein, helps clot blood. 
 
Fibrinogen – A soluble plasma glycoprotein. 
 
Healthcare Common Procedure Coding System (HCPCS) – A standardized 
classification system used for claims processing. 
 88
 
HEPES – Organic chemical that adjusts the pH of a solution. 
 
Human Mesenchymal Stem Cells (hMSCs) – These are cells that can differentiate into 
many cell types; these cells can be isolated from bone marrow. 
 
Immunoresponse – When the immune system detects a foreign body and produces 
antibodies to attack it; whether or not it is beneficial to the patient.  
 
Infarct – An area of tissue that is dead due to lack of blood and oxygen flow. 
 
Ischemia – A restriction in blood supply that causes damage or death to tissue. 
 
Medicare – A federal health care insurance program that provides coverage for people 
aged 65 years or older.  
 
Minimally Invasive – A procedure that is less invasive than open surgery (where the 
surgeon opens the tissue to have direct access to the organs) but still accomplishes the 
same goal. This is not the same as non-invasive, which does not break the skin. 
 
Myocardial Infarction – A heart attack; death of cardiac tissue 
 
Myocardium – The heart’s muscular wall (the middle layer in the heart), contracts 
causing heart to pump. 
 
Necrosis – Death of cells or living tissue. 
 
Neurons – Responsive cells in the nervous system that transmit information through 
electrochemical signaling. 
 
Oligodendrocytes – Insulate axons in the central nervous system.  
 
Platform Technology – A technology that can be applied in multiple fields, rather than 
just one.  
 
Scaffold – A temporary framework that provides support. 
 
Suture – Thread structures that sewn through portions of the human body together after 
they have been severed from injury, surgery or incisions to hold the flaps together and 
allow for healing.  
 
Thrombin – A protein that converts fibrinogen to fibrin. 
 
Vascular – Relating to the blood vessels of the body.  
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VIII Appendices 
VIII.1  Interview with Professor Gaudette 
 
Inquire about RNIH, CUTTOR, MTTC feedback 
He provided hard copies of the responses, which are located in the MQP binder.  
 
What are the advantages/benefits of the Microthreads? 
Microthreads deliver cells directly into the inner heart wall, where the infarcted tissue 
causes the greatest damage and problems. The threads accomplish this in a much more 
direct way than any other device in trials thus far. Injection techniques just have the cells 
pumped out of the heart as soon as the needle is pulled out. Balloon stents allow for 
enough time for a few cells to attach before it is pulled out and the cells float away. The 
IV application of cells does not allow for many cells to make it to the heart let alone 
attach to the inner heart wall (and there is the additional risk that the heart cells will 
attach to the lungs!). The other prominent technique is a heart patch that is highly 
invasive and does not leave much room for error. It requires removing the dead portion of 
the heart, and sewing new, healthy tissue into the gap. While this gets rid the damaged 
tissue, the perimeter of the patch will be highly subject to potentially breaking off due to 
the strain and stresses the heart would put on the sutures.  
 
Can Microthreads be sutured into the heart in a minimally invasive way? 
Right now, no. But they could be used that way in the future, through the use of cardiac 
endoscopes. This procedure would be performed by a cardiologist, and not a surgeon. 
Surgeons are in charge of the highly invasive tasks.  
 
-Side note: Learned that there is strong competition between cardiologists and surgeons, 
they try to keep their customers unless they absolutely have to send them so someone 
else. Cardiologists are the ones that refer patients to the surgeons.  
 
Do/will the cells sheer off when passed through the heart tissue? 
This is testing that they still need to do. They were hoping to use some of the grant 
money to further research this portion, however, there are some theories and ideas that 
they already have regarding the sheering of the seeded cells. It is believed that the cells 
will in fact sheer off when passed through the tissue of the heart. In order to preempt this, 
they are planning on creating protective sheaths that will cover the threads that will 
prevent the cells from sheering off. This sheath will allow O2 to pass through so that the 
cells will stay alive, but will not allow the cells to pass through the wall. This sheath will 
then be pulled out once the threads have been sutured into the heart wall.  
 
Are the strings strong enough to withstand the contractions of the heart? 
Yes, they are strong enough. As a matter of fact, they also allow for a little bit of give, so 
it can beat with the heart.  
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Will they damage the heart if sutured in too tightly? By constricting the muscle 
movement? 
Movement is constricted by scar tissue that forms around the punctures created by 
sutures. It is unknown as of now whether the Microthreads will create this type of 
scarring or not. This is something that further studies are needed for.  
 
Are Microthreads able to repair small amounts of dead tissue, or large amounts? 
As of now, this is not known. Further research is required in this area.  
 
Additional Information Given About Microthreads: 
§ Bundled together in groups of 10, and then looped through a needle (so that the 
threads are basically a bundle of 20).  
§ After about 3 days, the maximum amount of cells present on the threads, any 
longer and they run out of room to grow and begin to die.  
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VIII.2  Questions Answered by Professor Marsha Rolle 
 
What is the approximate amount of money that has gone into developing 
Microthreads? (***In order to determine how much development-expenses will 
factor into the potential pricing of the device) 
 
GP 
 
How can the Microthreads be manufactured on a larger scale? How many can be 
made at one time? 
 
GP 
 
 
If clinical trials were to occur, would the Microthreads have to be manufactured on 
location? 
 
No – I think it would be too difficult/not feasible.  I envision manufacturing these in a 
GLP/GMP facility and spending the time/money/effort to design systems for packaging 
and transporting them.  We have started doing this on a small scale for research purposes 
with a collaborator in New York.  However, cell-seeding (i.e., with the patient’s own 
cells) may be performed on site (this is what our collaborator is doing). 
 
 
If yes to previous question, what type of training would people have to undergo to 
be able to manufacture the threads correctly? Or would it have to be accomplished 
close to WPI so that the Microthreads could be manufactured correctly? 
 
See above. 
 
 
What is the current shelf-life of a Microthread?  
 
Not known exactly, and will probably depend on whether cells and serum are present.  
The half life of a dry thread is much longer than a hydrated thread, and cell-seeded 
threads only last for days.  Again, I think that making, sterilizing and shipping dehydrated 
threads may be more feasible than hydrated, cell-loaded threads.  Hydrated, cell-seeded 
threads will probably need to be made, packaged, shipped overnight and used within a 
day or two. 
 
 
What time frame does a Microthread have to be used at its optimal point of life 
(when it would be the most effective)?  
 
See above. 
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How long does it take to make a Microthread currently? 
 
GP. 
 
How long would it take to create a Microthread with the patient’s own adult 
mesenchymal stem cells upon the surface? 
 
Again, for this application, I imagine dry threads may be hydrated and seeded on site.  
 
 
What kind of precautions have to be taken to create a Microthread? 
 
GP.   
 
How sterile must the environment be? What is the likelihood of contamination? 
 
Threads can be sterilized after the process, but ideally, the process should be done 
aseptically. 
 
How old does the infarct need to be before the sutures can be put into place? Does 
the infarct have to be scarred over or can it be sutured in while the heart tissue is 
still dying? What does the timeline for infarct-repair look like?  
 
Scar will probably be harder to suture into than provisional matrix/early wound healing 
tissue/acute infarct.  The time course of infarct “healing” in humans takes several months 
– the acute phase occurs in the first few weeks. 
 
 
Is there a size limitation as to the how large of an infarct the Microthreads will 
repair? 
 
There may be a point where it is no longer feasible (cost of microthreads needed is too 
high to justify).  Also, if too many microthreads are sutured into the heart, it may 
compromise the strength of the tissue. 
 
Does the scar tissue have to be removed before the Microthread sutures are sewn 
into the heart wall? 
 
No – our ideal application would be to suture without surgical resection of the scar.  This 
would be less “invasive”. 
 
 
Where will the Collagen and/or Fibrin that the threads will be made of come from? 
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GP.  I think we discussed this – ideally from human sources, although bovine products 
are approved by the FDA. 
 
If it is not autologous, will there be an immuno-response in the patient? 
 
GP.  Again, bovine materials are approved for use in human patients. 
 
How are the threads sterilized? How will the threads remain sterilized? 
 
Right now, alcohol is used for our “bench top” sterilization procedures.  We have not 
experimented with packaging or other methods, so we don’t know how they will affect 
thread stability.  Ethylene oxide gas may be an option if there are no cells on the threads. 
 
 
Any information on the pricing of some of the competitors.  
 
Don’t know. 
 
 
Microthreads vs. the Heart Patch: first hand opinion on both. 
o pricing for Heart Patch? 
 
???  As we discussed, a potential advantage of a thread over a patch is that the patch is 
epicardial, but the threads can be placed anywhere within the heart wall. 
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VIII.3  Questions: Professors Pins & Gaudette in Collaboration 
(sent in conjunction with individual answers) 
 
What is the approximate amount of money that has gone into developing 
Microthreads? (***In order to determine how much development-expenses will 
factor into the potential pricing of the device) 
To date, we have spent $23,400 (in the form of a grant) on the development of these 
threads.  We anticipate receiving a second grant for $405,000 that we allow us to scale up 
and validate these threads in an animal model. 
 
How can the Microthreads be manufactured on a larger scale? How many can be 
made at one time? 
 
Unfortunately, I do not have a good answer for this at present. 
 
 
If clinical trials were to occur, would the Microthreads have to be manufactured on 
location? 
 
NO 
 
What is the current shelf-life of a Microthread?  
 
We have not analyzed this, but I think that 14-28 days is a reasonable estimate. 
 
 
What time frame does a Microthread have to be used at its optimal point of life 
(when it would be the most effective)?  
 
Again, we have not analyzed this.  I would presume that their properties remain constant 
for 14- 28 days. 
 
 
How long does it take to make a Microthread currently? 
 
Fibrin microthreads take approximately 24 hours to make. 
Collagen threads take approximately 3 days to make. 
 
How long would it take to create a Microthread with the patient’s own adult 
mesenchymal stem cells upon the surface? 
 
 
Threads can be ready at anytime, but it takes weeks to grow up stem cells once they have 
been isolated. 
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What kind of precautions have to be taken to create a Microthread? 
 
The starting material must come from a controlled, screened (virus-free, pathogen-free) 
and reproducible animal source. 
 
How sterile must the environment be? What is the likelihood of contamination? 
 
Must be sterile. There can be no likelihood of contamination. 
 
How old does the infarct need to be before the sutures can be put into place? Does 
the infarct have to be scarred over or can it be sutured in while the heart tissue is 
still dying? What does the timeline for infarct-repair look like?  
 
This is currently unknown.  
 
 
Is there a size limitation as to the how large of an infarct the Microthreads will 
repair? 
 
Not currently known. 
 
 
Does the scar tissue have to be removed before the Microthread sutures are sewn 
into the heart wall? 
 
Hopefully not. 
 
 
Where will the Collagen and/or Fibrin that the threads will be made of come from? 
 
I anticipate that the collagen and the fibrin will come from either a bovine or a human 
source.  
 
If it is not autologous, will there be an immuno-response in the patient? 
 
Depends on the stem cells that are being delivered. 
 
How are the threads sterilized? How will the threads remain sterilized? 
 
At present, threads are ethanol or isopropanol sterilized. The remain sterile be being 
handled using strictly sterile protocols after sterilization. 
 
 
Any information on the pricing of some of the competitors.  
 
No none competitors. 
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Microthreads vs. the Heart Patch: first hand opinion on both. 
o pricing for Heart Patch? 
 
Depending on size of patch, ~$500-1,000 for heart patch without cells. 
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VIII.4  Questions: Professor Glenn Gaudette January 21, 2009 
 
If clinical trials were to occur, would the Microthreads have to be manufactured on 
location? 
 
NO 
 
How sterile must the environment be? What is the likelihood of contamination? 
 
Must be sterile. There can be no likelihood of contamination. 
 
How old does the infarct need to be before the sutures can be put into place? Does 
the infarct have to be scarred over or can it be sutured in while the heart tissue is 
still dying? What does the timeline for infarct-repair look like?  
 
This is currently unknown.  
 
 
Is there a size limitation as to the how large of an infarct the Microthreads will 
repair? 
 
Not currently known. 
 
 
Does the scar tissue have to be removed before the Microthread sutures are sewn 
into the heart wall? 
 
Hopefully not. 
 
 
If it is not autologous, will there be an immuno-response in the patient? 
 
Depends on the stem cells that are being delivered. 
 
 
Any information on the pricing of some of the competitors.  
 
No none competitors. 
 
 
Microthreads vs. the Heart Patch: first hand opinion on both. 
o pricing for Heart Patch? 
 
Depending on size of patch, ~$500-1,000 for heart patch without cells. 
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VIII.5  E-mail Correspondence with Pharmacist Matthew Moen 
 
Lanoxin is the brand name for digoxin, digitek is a branded generic. Cardoxin is not a 
name I'm familiar with, it appears dipyridamole is marketed under this brand name in 
Israel (totally different drug than digoxin). Digoxin is available in 0.125mg and 0.25mg 
tablets. #30 0.125mg tablets = $15.13 
 
These are 3 different formulations of isosorbide dinitrate (available as a generic). 
Isosorbide dinitrate is available in 5, 10, 20, and 40mg tablets, typically dosed 2 to 3 
times daily. #30 20mg tablets = $17.07 
 
Apresoline is a brand name for hydralazine (available as a generic). It is available in 10, 
25, 50, and 100mg tablets. Dosing can vary significantly depending upon the condition 
being treated but the maximum is typically 300mg per day delivered in divided doses. 
#30 of the 50mg tablets = $26.90 
Apresazide is a combination of hydralazine & hydrochlorothiazide. Unfortunately it's not 
stocked by our wholesaler so I can't offer any pricing. 
 
BiDil is a combination of isosorbide dinitrate and hydralazine, available in a 20mg-
37.5mg tablet. Typical dosing is 1 tablet 3 times daily. Cost for #30 tablets = $77.50 
 
Bumetanide is available in 0.5mg, 1mg, and 2mg tablets, typically dosed once daily. #30 
1mg tablets = $23.36 
 
Chlorothiazide is available in 250mg and 500mg tablets. Typical dosing is 500 to 
1000mg once to twice daily. #30 500mg tablets = $17.95 
 
Hydrochlorothiazide is available in 12.5mg, 25mg, and 50mg formulations, typically 
dosed once daily. #30 25mg tablets = $12.38 
 
Spironolactone is available in 25, 50, and 100mg tablets, typically dosed once daily. #30 
50mg tablets = $34.47 
 
Eplerenone is available in 25 and 50mg tablets, typically dosed once daily. #30 25mg 
tablets = $133.07 
 
Let me know if there's any other information you require. 
 
Matt 
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VIII.6  ACEI Cost Table 
 
Generic Name 
and Dose
Brand Name
Frequency of Use
(per day)
Average Monthly 
Cost
Captopril 12.5 mg Capoten three $133
Captopril 12.5 mg Generic three $30
Captopril 25 mg Capoten three $131
Captopril 25 mg Generic three $31
Captopril 50 mg Capoten three $220
Captopril 50 mg Generic three $44
Captopril 100 mg Capoten three $271
Captopril 100 mg Generic three $55
Lisinopril 10 mg Prinivil one $38
Lisinopril 10 mg Zestril one $40
Lisinopril 10 mg Generic one $18
Lisinopril 20 mg Prinivil one $41
Lisinopril 20 mg Zestril one $44
Lisinopril 20 mg Generic one $20
Lisinopril 30 mg Zestril one $59
Lisinopril 30 mg Generic one $26
Lisinopril 40 mg Prinivil one $59
Lisinopril 40 mg Zestril one $61
Lisinopril 40 mg Generic one $27
Ramipril 1.25 mg Altace one $44
Ramipril 2.5 mg Altace one $50
Ramipril 5 mg Altace one $54
Ramipril 10 mg Altace one $65
Trandolapril 1 mg Mavik one $41
Trandolapril 2 mg Mavik one $42
Trandolapril 4 mg Mavik one $41
ACEI Cost Comparison Table
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VIII.7  Beta-Blocker Cost Table 
 
Generic Name 
and Dose
Brand Name
Frequency of 
Use
Average Monthly 
Cost
Atenolol 25 mg Tenormin One a day $47
Atenolol 25 mg Generic One a day $10
Atenolol 50 mg Tenormin One a day $47
Atenolol 50 mg Generic One a day $10
Atenolol 100 mg Tenormin One a day $71
Atenolol 100 mg Generic One a day $13
Carvedilol 6.25 mg Coreg Two a day $124
Carvedilol 12.5 mg Coreg Two a day $124
Carvedilol 25 mg Coreg Two a day $122
Metoprolol tartrate 
50 mg Lopressor One a day $35
Metoprolol tartrate 
50 mg Generic One a day $9
Metoprolol tartrate 
100 mg Lopressor One a day $52
Metoprolol tartrate 
100 mg Generic One a day $12
Propranolol 10 mg Inderal Two a day $33
Propranolol 10 mg Generic Two a day $12
Propranolol 20 mg Inderal Two a day $44
Propranolol 20 mg Generic Two a day $13
Propranolol 40 mg Inderal Two a day $56
Propranolol 40 mg Generic Two a day $15
Propranolol 60 mg Inderal Two a day $79
Propranolol 60 mg Generic Two a day $22
Propranolol 80 mg Inderal Two a day $87
Propranolol 80 mg Generic Two a day $20
Propranolol 
(sustained release) 
80 mg Inderal One a day $52
Propranolol 
(sustained release) 
80 mg Generic One a day $36
Propranolol 
(sustained release) 
120 mg Inderal One a day $64
Propranolol 
(sustained release) 
120 mg Generic One a day $40
Timolol 10 mg Blocadren Two a day $69
Timolol 10 mg Generic Two a day $25
Timolol 20 mg Blocadren Two a day $72
Timolol 20 mg Generic Two a day $45
Beta-Blocker Cost Comparison Table
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VIII.8  Digoxin, Diuretics and Aldosterone Cost Tables 
 
Generic Name 
and Dose
Brand Name
Frequency of Use
(per day)
Average Monthly 
Cost
Digoxin 0.125mg Digoxin 1 $15.13
Digoxin 0.25mg Digoxin 1 $20.70
Digoxin Cost Comparison Table
 
 
Generic Name 
and Dose
Brand Name
Frequency of Use
(per day)
Average Monthly 
Cost
Bumetanide 0.5mg 1
Bumetanide 1mg 1 $23.36
Bumetanide 2mg 1
Chlorothiazide 250mg
500mg - 1000mg, 
1 to 2
Chlorothiazide 500mg
500mg - 1000mg, 
1 to 2 $17.95 - $35.90
Hydrochlorothiazide 12.5mg 1
Hydrochlorothiazide 25mg 1 $12.38
Hydrochlorothiazide 50mg 1
Diuretics Cost Comparison Table
 
 
Generic Name 
and Dose
Brand Name
Frequency of Use
(per day)
Average Monthly 
Cost
Spironolactone 25mg 1
Spironolactone 50mg 1 $34.47
Spironolactone 100mg 1
Epleremone 25mg 1 $133.07
Epleremone 50mg 1
Aldosterone Antagonists Cost Comparison Table
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VIII.9  Isosorbide, Hydralazine and Combination Cost Table 
 
Generic Name 
and Dose
Brand Name
Frequency of Use
(per day)
Average Monthly 
Cost
Isosorbide Dinitrate 5mg Isosorbide Dinitrate 2 to 3
Isosorbide Dinitrate 10mg Isosorbide Dinitrate 2 to 3
Isosorbide Dinitrate 20mg Isosorbide Dinitrate 2 to 3 $34.14 to $51.21
Isosorbide Dinitrate 40mg Isosorbide Dinitrate 2 to 3
Isosorbide Dinitrate Cost Comparison Table
 
 
Generic Name 
and Dose
Brand 
Name
Frequency of Use
(per day)
Average 
Monthly Cost
Hydralazine 10mg Apresoline 300mg/day
Hydralazine 25mg Apresoline 300mg/day
Hydralazine 50mg Apresoline 300mg/day $4,842.00
Hydralazine 100mg Apresoline 300mg/day
Hydralazine Cost Comparison Table
 
 
Generic Name 
and Dose
Brand 
Name
Frequency of Use
(per day)
Average 
Monthly Cost
BiDil 20mg - 37.5mg 1 $77.50
I.D. & Hydralazine Cost Comparison Table
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VIII.10 Medication Yearly Costs: Minimum, Mean, Maximum 
 
ACEI 1 year
Lisinopril 10 mg $18.00 $216.00
Captopril 100 mg $271.00 $3,252.00
Ramipril 10 mg $65.00 $780.00
BETA
Metoprolol tartrate 50 mg $9.00 $108.00
Carvedilol 12.5 mg $124.00 $1,488.00
Atenolol 50 mg $47.00 $564.00
Digoxin
Digoxin 0.125mg $15.13 $181.56
Digoxin 0.25mg $20.70 $248.40
Diruetics
Bumetanide 1mg $23.36 $280.32
Chlorothiazide 500mg $17.95 $215.40
Chlorothiazide 500mg $35.90 $430.80
Hydrochlorothiazide 25mg $12.38 $148.56
Aldosterone Antagonists
Spironolactone 50mg $34.47 $413.64
Epleremone 25mg $133.07 $1,596.84
Isosorbide Dinitrate
Isosorbide Dinitrate 20mg $34.14 $409.68
Isosorbide Dinitrate 20mg $51.21 $614.52
Hydralazine
Hydralazine 50mg $4,842.00 $58,104.00
ID/H combo.
BiDil 20mg - 37.5mg $77.50 $930.00  
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VIII.12 Common Medication Combination Costs for Median 
Survival Years 
 
Medication 
Combinations Cost per year
Digoxin 7.4† 10.4‡ 6.4* 2.0#
Digoxin 0.125mg $182 $1,344 $1,888 $1,162 $363
Digoxin 0.25mg $248 $1,838 $2,583 $1,590 $497
Digoxin + ACEI
Digoxin 0.125mg 
+  
Lisinopril 10 mg
$398 $2,942 $4,135 $2,544 $795
Digoxin 0.125mg 
+  
Captopril 100 mg
$3,434 $25,408 $35,709 $21,975 $6,867
Digoxin 0.125mg 
+  
Ramipril 10 mg
$962 $7,116 $10,000 $6,154 $1,923
Digoxin 0.25mg 
+  
Lisinopril 10 mg
$464 $3,437 $4,830 $2,972 $929
Digoxin 0.25mg 
+  
Captopril 100 mg
$3,500 $25,903 $36,404 $22,403 $7,001
Digoxin 0.25mg 
+  
Ramipril 10 mg
$1,028 $7,610 $10,695 $6,582 $2,057
Digoxin + BETA
Digoxin 0.125mg 
+  
Metoprolol tartrate 50 mg
$290 $2,143 $3,011 $1,853 $579
Digoxin 0.125mg 
+  
Carvedilol 12.5 mg
$1,670 $12,355 $17,363 $10,685 $3,339
Digoxin 0.125mg 
+  
Atenolol 50 mg
$746 $5,517 $7,754 $4,772 $1,491
Digoxin 0.25mg 
+  
Metoprolol tartrate 50 mg
$356 $2,637 $3,707 $2,281 $713
Digoxin 0.25mg 
+  
Carvedilol 12.5 mg
$1,736 $12,849 $18,059 $11,113 $3,473
Digoxin 0.25mg 
+  
Atenolol 50 mg
$812 $6,012 $8,449 $5,199 $1,625
Median Survival Years
† Median patient survival years for women 60-69yrs, men 70-79yrs
‡ Median patient survival years for women 70-79yrs
* Median patient survival years for women ≥ 80yrs
# Median patientsurvival years for men ≥ 80yrs
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VIII.13 E-mail Correspondence for Collagen Pricing 
 
We have received your product interest from Biocompare. 
 
Attached for your review, please find a data sheet for our Human Collagen Type IV, Catalog 
#A33125H ($525.00/0.5mg) and Bovine Collagen Type III, Catalog #A33124B 
($231.00/0.5mg). 
 
Please note that United States customers may view pricing on-line after registering on our 
website. 
 
Should you have any questions or need additional information, please do not hesitate to 
contact us or visit our website www.meridianlifescience.com. 
 
Best Regards, 
 
Anne Daley 
Account Support Specialist 
Meridian Life Science, Inc. 
60 Industrial Park Road 
Saco, ME 04072 
  
Phone: 207-283-6500 Fax: 207-283-4800 
e-mail: info@meridianlifescience.com 
Website: www.meridianlifescience.com 
 
Please note regarding pricing/specs: 
Quote effective for 30 days 
Price quoted in US dollars 
Payment terms: With approved credit: net 30 days from invoice date.  All others: Prepay 
FOB Saco, ME, Freight PPD/ADD 
Handling (one box) $25.00, additional box $15.00 
Dry Ice charge: $20.00 if applicable 
Price based upon full quantity in a single shipment. 
 
Do you need a HAMA Blocker manufactured to your specifications? Contact us via 
http://meridianlifescience.com/products/hama.asp 
 
A ISO 9001:2000 Certified company 
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VIII.14 SPECIFICATION SHEET: Collagen Type IV 
 
Important Note: Centrifuge before opening to ensure complete recovery of vial 
contents. 
 
 
Catalog #: A33125H                                              Lot #:      1L34408 
 
Description:  Human Collagen Type IV 
 
Source:  Placental villi 
 
Format: Purified, Liquid 
 
Purification: >90% pure (SDS-PAGE) 
 Controlled and limited pepsin digestion, followed by selective salt precipitation 
 
Concentration:  0.5mg/ml (dry weight) 
 
Buffer:   500mM Acetic acid 
 
Preservative:  None 
 
Application: Type IV collagen standard 
 Antigen for antibody production 
 Coating material for cell culture studies 
 Formation of collagen gels 
 Each laboratory should determine an optimum working titer for use in its 
particular application. Other applications have not been tested but use in such 
assays should not necessarily be excluded. 
 
Storage: The collagen may be transferred into physiological buffers by dialysis at 2–8°C. 
Purified collagen may be stored for several months at 2–8°C without appreciable 
loss of activity. For long term storage, aliquot and store at -20°C. Avoid multiple 
freeze/thaw cycles. 
 
Inactivation: Pepsin digestion and storage in 500mM Acetic acid 
 
Warnings:  All materials should be handled as if potentially infectious. Generally accepted 
laboratory practices appropriate for infectious materials should be employed 
when handling this product. 
 
References: The references listed below are for research purposes only. 
1. Miller, E.J., et al., 1982, Meth. Enzymol. 82:33–64. 
2. Miller, E.J., In: Extracellular Matrix Biochemistry, K.A. Piez and A.H. 
Reddi, eds. Elsevier, New York, 1984. Pp. 41–81. 
 
 
 
1.0  FOR RESEARCH USE ONLY. NOT FOR USE IN 
DIAGNOSTIC PROCEDURES. 
12/9/08 
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VIII.15 SPECIFICATION SHEET : Collagen Type III 
 
 
Important Note: Centrifuge before opening to ensure complete recovery of vial 
contents. 
 
 
Catalog #: A33124B                                                      Lot #:    13B03708 
 
Description:  Bovine Collagen Type III 
 
Source:  Placental villi 
 
Format: Purified, Liquid 
 
Purification: >90% (SDS-PAGE analysis).  Controlled and limited pepsin digestion, followed 
by selective salt precipitation. 
 
Concentration:  0.5mg/ml (determined by dry weight) 
 
Buffer:   500mM acetic acid 
 
Preservative:  None 
 
Applications:   Type III collagen standard 
 Antigen for antibody production 
 Coating material for cell culture studies 
 Formation of collagen gels 
 To ensure lot-to-lot consistency, each lot of purified collagen is tested for 
conformance with characteristics of a standard reference reagent using SDS-
PAGE analysis. 
 
Storage: The collagen may be transferred into physiological buffers by dialysis at 2-8°C.  
Store at 2-8°C for several months without appreciable loss of activity.  For long 
term storage, aliquot and store at –20°C.  Avoid multiple freeze/thaw cycles. 
 
Inactivation:  Not applicable. 
 
References: The references listed below are for research purposes only.   
1. Miller, E.J. and Rhodes, R.K. (1982), Methods in Enzymology, 82:33-64. 
2. Miller, E.J. In: Extracellular Matrix Biochemistry, K.A. Piez and A.H. 
Reddi, Eds (Elsevier/New York, 1984) pp. 41-81. 
 
 
 
 
 
 
1.1  FOR RESEARCH USE ONLY.  NOT FOR USE IN 
DIAGNOSTIC PROCEDURES. 
2/6/08 
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VIII.16 Microthread Business Plan 
 
Executive Summary 
§ 1 paragraph explaining the product. 
§ 1 summary paragraph for each tab within the plan. 
o Segmenting with minor-headings to separate the paragraphs can be used. 
Company Description 
Company name: Name of the Company 
Form of Organization: (Partnership, S Corporation, LLP, etc.) 
Ownership: Who owns the company? (ex. George Pins, etc.) 
Location: Where is the business located/headquartered? 
Definition of the business: What will the company be creating, why? 
Company goals: Overall goals of product in next 5-10 years. 
Future Plans: Development of business and product. 
Milestones 
§ Income, development, insurance coverage, FDA approval, etc. 
Marketing Tab – Most found in this Major Qualifying Project 
Overall Marketing Strategy 
Market Segmentation and Target Market 
Competition Analysis 
Intellectual Property Analysis 
Licensing 
Sales and Distribution Tab 
Sales Process  
Key Players 
Distribution 
Management Tab 
Management Team 
Company Structure 
Professionals 
Operations Tab 
Operation Model and Procedures 
Manufacturing 
Vendors and Suppliers 
Business Location 
Financial Tab 
Revenue 
Expenses 
§ Cost to manufacture, packaging, shipping expenses, etc. 
§ Salaries, R&D, administrative 
Five Year Financial Projection 
§ Graph and table of data, as well as an explaination 
Risks 
The potential risks and ways the risks can be mitigated.  
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VIII.17 HCPCS Request Questionnaire 
 
Alpha-Numeric HCPCS Coding Recommendation Format INFORMATION 
SUPPORTING CODING MODIFICATION RECOMMENDATION 
1. For the purpose of publication on our request list and public meeting agenda on the 
HCPCS website, please provide a brief summary of your request (not to exceed 300 
words). In this summary, please specify your request to modify the HCPCS code set: (e.g. 
number ofnew codes requested, recommended language; revise a code (provide old 
language and recommended language), discontinue a code). Include the name of the 
product, description, function, and the reason why existing codes do not adequately 
describe your product. For drugs, include the indications for use, action, dosage and route 
of administration, and how supplied. Text that exceeds the 300-word limit may be 
truncated and not appear on our published summary, therefore, it is important to provide 
a concise summary within the 300word limit. CMS may edit your summary prior to 
publication. 
 
2. Identify the Item (product or drug/biological) for which a Level II HCPCS Code is 
being requested. 
A) Trade or Brand Name: 
B) General Product Name or Generic Drug Name (active ingredient): 
C) FDA classification: 
D) Drug or Biological Y/N 
 
3. Please check one HCPCS category from the following list, which most accurately 
describes the item identified in question #1: 
 __ A) Medical/Surgical Supplies 
 __ B) Dialysis Supplies and Equipment 
 __ C) Ostomy/Urological Supplies 
 __ D) Surgical Dressing  
 __ E) Prosthetic 
 __ F) Orthotic 
 __ G) Enteral/Parenteral Nutrition 
 __ H) Durable Medical Equipment 
 __ I) Blood/Blood Products 
 __ J) Drug/Biological 
 __ K) Radiopharmaceutical 
 __ L) Vision 
 __ M) Hearing 
 __ N) Other (please indicate/provide category)_________________________________ 
 
4. Is the item durable, if so, explain how it can withstand repeated use? 
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5. Describe the item fully in general terminology. What is it? What does it do? How is it 
used? Describe the patient population for whom the product is clinically indicated. 
Descriptive booklets, brochures, package inserts, as well as copies of published peer- 
reviewed articles on the item may be included in the information packet submitted for 
review, but they do not replace the requirement to fully respond to this question and fully 
describe the item. 
For drugs and biologicals, include: A) indications for use, B) action, C) dosage and route 
of administration, D) package insert and, E) how supplied. 
 
6. Describe how the item/product is primarily and customarily used to serve a medical 
purpose. 
7A) Identify similar products and their manufacturers. 
(If a drug - list other drugs by trade name marketed under the same active ingredient 
category/generic name.) 
7B) Identify significant differences between this item and other products listed above. 
(Include differences in item cost; material; product design; how it is used; different 
mechanism of operation, differences in function/treatment provided to a patient; clinical 
indication; and clinical outcome.) 
7C) Complete item 7C only if you are making a claim of significant therapeutic 
distinction). 
Claims of significant therapeutic distinction when compared to the use of other, similar 
items, must be described in detail. Articulate the clinical theory behind the claim, 
including differences in the product or its operation as it compares to currently coded 
products. Specify how the product results in a significantly improved medical outcome or 
significantly superior clinical outcome. (Please refer to the HCPCS decision tree for 
additional information.) Provide the best available information related to your claim. 
Include copies of all articles that result from your systematic analysis of the available 
literature. Information submitted should be as complete as possible. Unfavorable articles 
should be provided with any appropriate rebuttal or explanation. If the articles submitted 
cause you to exceed the overall 40-page limit, then submit one reference copy of each 
article and 35 copies of the application. 
 
8. Answer each of the questions A), B), and C) below: 
A) List any 3rd party payers that pay for this product 
B) List any codes that are currently being billed to those payers for this product. 
C) Explain why existing code categories are inadequate to describe the item. 
 
9. 
A) Is this product prescribed by a health care professional? 
B) If yes - who prescribes the product and in what setting(s) is the product prescribed? 
 
10. 
A) Is the item useful in the absence of an illness or injury? 
B) Explain: 
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11. Provide the date that the item/product was approved for marketing by the FDA. 
Attach copy of the FDA approval letter including the 510K summary for those items that 
are approved using the 510K process. If the product is exempt from FDA review and 
classification, please explain the basis for the exemption. Note: For drugs and biologicals 
only: FDA approval documentation may be submitted after the code application, but no 
later than March 31, 2009, provided all other application materials are complete and 
submitted by the deadline, and provided the application for marketing approval has been 
submitted to the FDA by March 31, 2008. Applicants awaiting FDA approval for drugs 
or biologicals at the January 5th submission deadline must submit with the application 
documentation evidencing submission for FDA approval, along with the date the 
application was submitted to the FDA. 
For all non-drug and biological items, the applicant must submit 3 months of marketing 
experience following the FDA approval date. 
 
12. When was the item/product marketed in the United States? 
**Note** Marketing data is not required for drugs and biologicals, however; the date of 
first sale is required. Prior to submitting this coding recommendation, what is the total 
number of units sold in the U.S. and the total dollar amount in sales (Medicare, Medicaid 
and private insurance)? Do not estimate or provide projections - the information provided 
must represent actual volume of sales for the product for the period of time indicated. 
 
13. Identify the percent of use of the item across the following settings for all 
nondrugs/biologicals. 
Physician's Office: _______ 
Freestanding Ambulatory Care Clinics: _______ 
Patient's Home by patient: _______ 
Patient's Home by Health Care Provider: _______ 
Nursing Home/Skilled Nursing Facility: ________ 
Hospital Inpatient Facilities: ________ 
Hospital Outpatient Facility: ________ 
Other- (identify): _________ 
TOTAL VOLUME OF USE ACROSS ALL SETTINGS SHOULD EQUAL 100% 
 
14.What is the Manufacturer’s Suggested Retail Price (MSRP) or list price of the item? 
This question must be answered for all items, except drugs/biologicals. 
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HCPCS Coding Recommendation submitted by: 
* Please provide a complete mailing address and direct dial phone number. We use this 
information to contact applicants regarding upcoming meetings, questions regarding 
applications, and to make notifications of the status of applications. Name: Name of 
Corporation/Organization: Mailing Address (street): City, State, Zip Telephone Number 
and extension: FAX Number: E-Mail Address: I attest that the information provided in 
this HCPCS coding recommendation is accurate and correct to the best of my knowledge. 
____________________________ _________________________Date:_____________ 
Signature of Applicant Is applicant the manufacturer? Y/N If not, the manufacturer must 
sign the following attestation: I attest that the information describing the product is 
accurate. ____________________________ 
_________________________Date:_____________ Signature of Manufacturer 
According to the Paperwork Reduction Act of 1995, no persons are required to respond 
to a collection of information unless it displays a valid OMB control number. The valid 
OMB control number for this information collection is 0938-1042. The time required to 
complete this information collection is estimated to average 11 hours per response, 
including the time to review instructions, search existing data resources, gather the data 
needed, and complete and review the information collection. If you have comments 
concerning the accuracy of the time estimate(s) or suggestions for improving this form, 
please write to: CMS, 7500 Security Boulevard, Attn: PRA Reports Clearance Officer, 
Mail Stop C4-26-05, Baltimore, Maryland 21244-1850. Revised – 4/10/08 
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VIII.18 HCPCS Details 
 
A company or individual has the option to submit a code request to the CMS by using a 
standard format which includes: 
§ Cover letter outlining the code request and briefly summarizing why 
the code is needed. 
§ Completely answer all questions located within Alpha-Numeric 
HCPCS Coding Recommendation Format Information Supporting 
Coding Modification Recommendation (see Appendix VIII.17).  
§ FDA approval letter. 
§ Supporting documentation and/or descriptive material to further 
understanding of the medical benefits of the item. 
§ No more than three samples of the product, video tapes or compact discs. 
§ Sign and date every recommendation. 
The entirety of the packet must be 40 pages or less in length or they will not be 
considered for coverage. Each side of a piece of paper counts as one page so one must be 
very careful in being direct and to the point. Every question in the recommendation 
format must be completely answered; if there are any questions answered with N/A, then 
the application will automatically be discarded. The committee does not accept electronic 
copies; therefore the entire packet of information must be printed out and bundled 
securely. Binders and other bulky binding materials are not accepted. Besides conforming 
to these requirements, the requester must submit an additional 35 complete copies of the 
recommendation packet so that the entire committee may review the topic65.  These 
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recommendations have approximately an eleven-month turnaround period from the point 
when they are submitted to that when the requester receives an answer.  
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